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Investigating Feeding Omega-3 Polyunsaturated Fatty Acids and/or Soy Protein 
Isolate to Female pck Rats on Polycystic Kidney Disease and Related Complications 
  
Kaitlin Hope Maditz 
     Polycystic kidney disease (PKD) is a genetic disorder characterized by 
multiple benign cysts along the epithelial lining of the kidneys.  As PKD progresses, cyst 
growth increases kidney volume, decreases renal function, and may eventually lead to 
end stage renal disease.  In addition to renal manifestations, PKD patients are at risk of 
complications that include bone loss and polycystic liver disease (PLD).  Currently, no 
genetic therapy or effective pharmacological treatments exist.  Therefore, dietary 
intervention offers a potentially efficacious, cost-effective, and safe therapeutic option for 
PKD and PKD-related complications.  Offering dietary treatment to attenuate PKD 
disease progression has the potential to improve renal function, preserve bone health, and 
to prevent PLD.  Dietary soy protein has been shown to reduce cyst proliferation and 
growth and to enhance bone mass.  Dietary omega-3 polyunsaturated fatty acids (n-3 
PUFA’s) have anti-inflammatory properties.  Dietary n-3 PUFAs have been shown to 
reduce PKD severity and may attenuate bone loss and PLD severity.  Therefore, the 
objectives of this thesis was to investigate the role of dietary soy protein and/or n-3 
PUFAs on PKD progression and severity and related complications of bone loss, and 
PLD using a pck rat model.  Young (age 28 d) female pck rats were randomly assigned 
(n=12/group) to diets consisting of casein + corn oil (Casein + CO), casein + soybean oil 
(Casein + SO), SPI + soybean oil (SPI + SO) or SPI + 1:1 soybean/salmon oil (SPI + SB) 
for 12-weeks.  Histological evaluation showed that all rats had renal and hepatic cysts 
regardless of the dietary group.  Rats fed SPI+ SB diet had the highest (P = 0.03) renal 
and hepatic cortical cyst obstruction.  Although, rats fed SPI+SB diet had the highest (P< 
0.001) renal docosahexaenoic acid (DHA) and highest (P<0.001) hepatic 
eicosapentaenoic acid (EPA) and DHA content, this did not reduce inflammation.  Gene 
expression of various transcription factors and inflammatory genes in the kidneys and 
liver was not significantly different among the dietary treatment groups.  Histological 
evaluation of hepatic and renal fibrosis and gene expression of fibrosis were also not 
significantly different among the dietary treatment groups.  However, rats fed SPI + SB 
diet had the highest (P < 0.01) serum blood urea nitrogen levels indicating reduced renal 
function.  Rats fed SPI + SB diet also had the highest liver total lipid (P < 0.001) and 
steatosis (P = 0.003) suggesting disordered lipid metabolism.  Rats fed SPI+SB diet had 
higher (P=0.01) calcium (Ca) and phosphorus (P) retention, but there were no significant 
differences in bone Ca, P, bone mass, bone microarchitecture or strength among the diet 
groups.  Based on the results, dietary soy protein and/or n-3 PUFAs did not attenuate 
PKD progression and severity or related complications of bone loss and PLD in the 
female pck rat model of PKD.  Furthermore, feeding SPI + SB diet was potentially 
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Polycystic kidney disease (PKD) is characterized by multiple benign cysts derived from 
the epithelial lining of the kidneys. Cysts can develop spontaneously as a consequence of aging, 
dialysis, medication, and hormones or can be the result of hereditary.1 In 2008, 547,982 patients 
in the United States were diagnosed with kidney disease and received treatment (i.e. dialysis or 
kidney transplant) for end stage renal disease (ESRD) at a cost of 39.46 billion dollars.2  Of those 
patients, approximately 22% of all ESRD cases were due to PKD.2  The most prevalent inherited 
forms of PKD are autosomal dominant polycystic kidney disease (ADPKD) and autosomal 
recessive polycystic kidney disease (ARPKD).  ADPKD manifests in early adulthood; whereas, 
the rarer ARPKD has infantile onset resulting in kidney failure before adulthood.3  In both forms 
of PKD, the accumulation of renal cysts results in massive kidney enlargement, structural 
damage, and loss of renal function.4   
PKD leading to ESRD, results in the need for long-term dialysis or kidney 
transplantation.5  PKD can also result in the development of various renal related complications.  
Compromised renal function could lead to increased mineral loss and in turn, decreased bone 
strength and health.  PKD can also result in the development of various extra-renal co-
morbidities and complications.  The most common extra-renal cyst manifestation of PKD is cysts 
in the liver.6  Given these various potential complications, PKD is a major health concern with 
detrimental outcomes. 
Common strategies for the management of renal disease and bone health in childhood are 
to promote a healthy body weight and to maximize peak bone mass (PBM).  Pharmacological 
therapies for PKD typically target cyst pathogenesis.  However, reports of the efficacy of 
pharmacological agents have been inconsistent.7
,8  Effective therapies should treat the disease, be 
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low in side effects, and improve related disease complications such as bone loss and liver cysts 
in PKD.  Diet intervention offers a potentially efficacious, cost-effective, and safe therapeutic 
option. 
Studies have examined the role of different protein and/or lipid sources as a diet strategy 
for decreasing PKD progression and severity using the Hans:SPRD-cy rat, an animal model of 
ADPKD.9,10  Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been reported to have anti-
inflammatory actions mediated through alterations in membrane composition, gene expression, 
and eicosanoid production.11,12  Male Han:SPRD-cy rats fed diets supplemented with n-3 PUFAs 
significantly decreased renal inflammation and damage.13  Feeding soy protein isolate (SPI) has 
been shown to reduce cyst proliferation and to decrease cyst growth in male PKD animal 
models.14,15  Feeding male Han:SPRD-cy rats soy protein slowed PKD progression by decreasing 
inflammation indicated by decreased renal cyclooxygenase-2 (COX-2) enzyme activity and renal 
prostanoids.15  To our knowledge, no studies have evaluated SPI and/or n-3 fatty acids on female 
pck rats.  This is of concern since females with PKD have a higher prevalence of severe 
polycystic liver disease (PLD) compared to males.6  Despite liver cysts being the most common 
extra-renal manifestation of PKD, no studies have examined the role of diet treatment on PLD 
progression.  Cyst pathogenesis in the liver is similar to PKD.6  Therefore, diet components such 
as SPI and n-3 PUFAs that have showed to attenuate cysts in PKD may also attenuate liver cysts.  
Furthermore, SPI and n-3 PUFAs have been found in pre-clinical studies to improve bone health 
and to attenuate bone loss leading to osteoporosis.16,17  The pck rat developed as a spontaneous 
mutation in Sprague-Dawley rats.18  Growing female Sprague-Dawley rats fed SPI enhanced 
bone mineral content (BMC) and bone mineral density (BMD) compared to casein.19  Previously, 
we reported that female Sprague-Dawley rats fed fish oil rich in the long-chain n-3 PUFAs, 
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eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaeonic acid (DHA, 22:6 n-3) increased 
femur and tibial BMD and BMC; whereas, flaxseed oil rich in the n-3 PUFA, alpha linolenic 
acid (ALA, 18:3n-3) improved long bone trabecular microarchitecture compared to rats fed corn 
oil.20  Female Han:SPRD-cy rats (age 21 d) fed ALA-rich flaxseed oil had higher whole body 
BMC and BMD compared to animals fed corn oil low in n-3 PUFAs.21  To our knowledge no 
studies have investigated the role of feeding soy protein and/or n-3 PUFAs on bone health in pck 
rats. 
Currently, no rodent model is genetically orthologous while expressing phenotypes 
typical of human ADPKD or ARPKD.  The pck rat model has a phenotype that resembles a slow 
progressing form of human ARPKD and PLD and also has characteristics of human ADPKD.22  
Although most dietary studies have used male rodent models, females with advanced PKD 
exhibit increased liver cyst progression and worsened PLD severity.6  Therefore, the objective of 
this dissertation is to examine the role of feeding soy protein and/or n-3 PUFA to female pck rats 












1.0. Literature Review 
1.1.  Renal Function  
Renal physiology and function has been reviewed in detail in Gigliotti (2011)23  Briefly, 
the functions of the kidney include regulation of blood volume, waste content, pH, electrolyte 
and mineral concentrations, and nutrient concentrations.  By regulating these components of the 
blood, the kidneys are the primary organ responsible for maintaining a constant composition of 
all extracellular fluids.  These functions are accomplished within specialized regions of the renal 
vasculature.  The nephron is composed of vascular and tubular portions which are involved in 
filtering the blood.  Healthy individuals have around 2 million nephrons; yet, only ~10% of this 
capacity is needed to support life.  Despite this large reserve capacity, millions of Americans 
suffer from inadequate renal function each year.24  Of particular interest to this research is the 
role of the kidneys on mineral balance. 
Ca and P reabsorption 
As described in Gigliotti (2011)
23
, the reabsorption of Ca and P occurs predominately in 
the proximal tubule.  Tubular P is reabsorbed in a sodium dependent co-transport mechanism, 
while Ca reabsorption primarily occurs via paracellular pathway.25  However, renal handling of 
Ca and P can also be influenced by hormonal signaling.  The major hormones involved in Ca and 
P metabolism are parathyroid hormone, vitamin D, and calcitonin.26  Generally, parathyroid 
hormone and vitamin D are involved in increasing serum Ca levels by influencing release of Ca 
and P from bone, increasing intestinal absorption of Ca, and decreasing urinary excretion of Ca.  
Increased urinary reabsorption of Ca is mediated by parathyroid hormone induced increase in Ca 
channels in the distal nephron.  Due to the toxic effects of elevated serum P, parathyroid 
hormone also stimulates urinary excretion of P to counteract the increase in serum P induced by 
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bone resorption.  On the other hand, calcitonin is released from the thyroid gland in the presence 
of high serum Ca.  The release of calcitonin triggers a general hypocalcemic response, which 
primarily involves decreased Ca release from bone.  
After losing a large portion of the solutes (i.e. organic nutrients, Ca, P, etc.) in the 
proximal tubule, the remaining filtrate eventually descends from the cortex of the kidney (cortex 
includes the glomerulus and both the proximal and distal convoluted tubules) into the medullary 
tissue (medulla includes both the descending and ascending Loops of Henle and the collecting 
ducts).  As the filtrate leaves the proximal tubule, it descends into the medulla via the descending 
limb of the Loop of Henle.  The Loop of Henle has varying properties, which contribute to the 
development and maintenance of the medullary characteristics.  The descending limb is water 
permeable.  Therefore, water diffuses out of the tubular lumen in response to the loss of solutes 
within the proximal tubule.  The filtrate then continues through the ascending limb, where 
sodium-chloride is actively pumped out of the lumen and into the interstitial space and associated 
capillaries.  The increased interstitial salinity is the driving force for water reabsorption from the 
kidney tubules.  This provides an ability to regulate water excretion, which is a key function of 
the kidneys.26 
Biomarkers of renal function 
Given the role of the kidney in maintaining blood composition, insufficient renal activity 
can influence multiple organ systems.  Therefore, monitoring renal function is of importance in 
both clinical and research settings.23  Serum markers of renal function include Ca, P, uric acid, 
total protein, albumin, and blood urea nitrogen (BUN).  BUN determines the filtrating ability of 
the kidney.  Urea is a waste product derived from the metabolism of amino acids, and is removed 
from the circulation through renal filtration.  Therefore, increases in BUN is a biomarker of renal 
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deficiency.  However, serum measures of total protein, albumin, Ca, and P are not specific to 
renal function.  For example, alterations in serum protein and albumin may result from liver 
abnormalities and not glomerular damage resulting in increased excretion of albumin.  Similarly, 
changes in serum Ca and P may result in pathologies associated with bone and or mineral 
metabolism. PKD is currently a leading genetic cause (5-10%) of end-stage renal disease 
(ESRD) in the United States.
27
 
Genetics and Pathogenesis of PKD 
The most common inherited renal disease, ADPKD is caused by mutations in either the 
PKD 1 (85% of cases) or PKD 2 (15% of cases) gene.8  PKD 2 gene mutation produces later 
onset of symptoms and slower disease progression than a defect in the PKD 1 gene.28  The PKD 
1 and PKD 2 gene encode cilia-associated membrane glycoproteins, polycystin-1 and 2, 
respectively.29  The less prevalent, but more severe ARPKD afflicting neonates and children is 
caused by a mutation in the PKHD1 gene encoding the cilia-associated membrane glycoprotein, 
fibrocystin.30  Cilia act as mechanosensors and therefore, the disruption of cilia in the kidneys 
affects various signaling pathways.31  Currently, the main pathways targeted for development of 
therapeutics to treat PKD are related to cyclic adenosine monophosphate (cAMP), mammalian 
target of rapamycin (mTOR) or epidermal growth factor receptor (EGFR) signaling.7  However, 
PKD involves multiple signal pathways due to the complex pathogenesis of cyst development 
and enlargement.  Shown in Figure 1, cyst pathogenesis includes aberrant epithelial proliferative 
rates, increased apoptosis, accumulation of fluid within the cysts, degradation of matrix 
components, and interstitial inflammation.32  Progressive cyst growth and the resulting fibrosis in 




Animal studies have advanced our knowledge of molecular mechanisms of PKD and 
potential therapeutic treatments.  Genetic rodent models of PKD have been generated from 
spontaneous mutations, transgenic technology, and gene-specific targeting.  Currently, none of 
the available rodent models fully meet the requirements of being both genetically orthologous 
and expressing phenotypes typical of human ADPKD or ARPKD.5  Table 1 shows characteristics 
of rodent models that have been useful in evaluating potential therapies for PKD.  
A dietary recommendation for PKD patients has been low protein diets.   The rationale is 
to prevent further renal injury and thereby, progression to ESRD.  Furthermore, protein 
restriction may inhibit cystogenesis.  Although protein restriction is a common dietary 
recommendation for PKD patients, its efficacy and safety is debated.  The next section reviews 
the role of low protein diets on PKD. 
PKD and Protein Restriction 
The role of diet on PKD has been published as a review by Maditz et al.34  Although 
protein restriction is a common dietary recommendation for PKD patients, its efficacy and safety 
is debated.  It is recommended that healthy individuals consume 0.8 to 1.5 g protein/kg body 
weight daily.  However, protein consumption exceeding 0.8 g/kg body weight has been 
suggested to negatively affect PKD by causing higher renal perfusion and kidney hyperfiltration 
of the already compromised nephron.35  Higher levels of protein (≥ 0.8 g/kg body weight) also 
stimulate renin activity, which increases circulating angiotensinogen and elevates blood 
pressure.36   According to Torres et al.37 the occurrence of renin in the epithelial lining of cyst 
walls raises the possibility that abnormal expression of the renin-angiotensin system may 
regulate epithelial hyperplasia in growing renal cysts.  Only a few animal studies, small clinical 
trials, and the MDRD study have investigated the amount of dietary protein on PKD.  Evaluating 
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the value of low protein diets on PKD progression is important because protein restriction may 
be associated with risk of protein malnutrition, particularly for ARPKD characterized by early 
onset that includes rapid growth stages. 
Tomobe et al.35 investigated the role of protein restriction on PKD progression using the 
pcy mouse model (Table 1).  Young (age 70 days) male pcy mice were randomly assigned 
(n=14/group) to be fed either a normal (25 g/100 g diet) or a low (6 g/100 g diet) protein diet 
with the milk protein, casein as the source.  The diets were adjusted to be isocaloric and were 
provided ad libitum throughout the 3.5 month study.  Feeding male pcy mice a low protein diet 
reduced kidney weight by 50% and cyst area by 40% compared to rats fed a normal protein diet.  
Increased cyst burden interferes with kidney function and eventually leads to renal failure.32  
Despite lower cyst area in pcy mice fed a low protein diet, there was no effect on renal function 
indicated by no significant differences in GFR, urine volume, and urinary protein and sodium 
concentrations (Table 2).  Protein intake was sufficient indicated by similar body weights and 
higher survival rates in pcy mice fed a low (310 ± 20 days) compared a normal (251 ± 16 days) 
protein diet. 
Using the Han:SPRD-cy another rodent model of PKD (Table 1), male rats (age 60 days) 
were randomly assigned (n=10/group) to be fed either a normal (20 g/100 g diet) or low protein 
(8 g/100 g diet) diet with casein as the protein source for 4 months.38  Renal volume corrected for 
body weight was significantly lower in rats fed a low (6.2 ± 1.64 ml/kg) compared to a normal 
(11.6 ± 5.02 ml/kg) protein diet.  Total cyst volume was significantly reduced in rats fed a low 
(0.47 ± 0.16 ml) compared to a normal (2.68 ± 0.87 ml) protein diet.  Renal function was also 
improved indicated by significantly lower urinary creatinine and urea concentration in rats fed a 
low compared to normal protein diet (Table 2).  However, body weights were significantly 
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decreased in male Han:SPRD-cy rats fed a low protein diet suggesting protein malnutrition.  The 
diets were adjusted to be isocaloric, but rats were fed ad libitum and food intake was not 
reported.  Therefore, reduced body weight may be due to reduced caloric rather than inadequate 
protein intake. 
Bankovic-Calic et al.39 evaluated renal tissue from the Ogborn and Sareen study38 using 
proliferating cell nuclear antigen-positive cells (PCNA) to determine cell proliferation.  Male 
Han:SPRD-cy rats fed a low protein diet had significantly fewer PCNA-positive cells (57.5 
cells/mm epithelium) than rats fed a normal protein diet (71.6 cells/mm epithelium).  Rats fed a 
low protein diet also had fewer (P= 0.006) apoptotic cells (31.2 cells/mm epithelium) compared 
to rats fed a normal protein diet (35.6 cells/mm epithelium).  Depicted in Figure 1, cyst 
pathogenesis is characterized by initial proliferation and apoptosis of tubular epithelial cells 
followed by inflammation and fibrosis as the disease progresses.40
,32  All male Han:SPRD (age 60 
days) showed histological evidence of renal inflammation and fibrosis, but there was less 
occurrence in animals fed a low protein diet.  The study results indicated that low protein intake 
attenuated cyst growth and expansion. 
Human studies investigating the effects of protein restriction on PKD have been limited 
in number.  Studies conducted in the 1980s with a small number of ADPKD subjects reported 
that protein restriction delayed progression to ESRD indicated by slower increases in serum 
creatinine concentration.  However, these studies also included other dietary changes such as 
keto acid supplementation41 and phosphorus restriction.42   In a larger study, Choukroun et al.43 
retrospectively analyzed 109 ADPKD dialysis patients (n=57 males, n=52 females, age 46.1 + 
0.9 years) for renal decline by measuring creatinine clearance (CrCl).  Measurement of CrCl 
from values of 30 to 50 ml/min/1.73 m
2
 until ESRD resulted in an average follow-up time of 6.7 
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+0.3 years.  The study results indicated that protein intake of 0.7 to 1.2 g/kg/day had no effect on 
progression to ESRD in patients with either advanced PKD or significantly impaired renal 
function.  This was in agreement with the MDRD study conducted to determine whether 
lowering dietary protein slows progression to chronic renal disease.  In the MDRD study, 
ADPKD participants (n=200) were followed for 2.2 years.44  GFR was measured monthly during 
the three month baseline.  Participants (n=141, age 40 to 49 years) determined to have a GFR 
range of 22 to 55 ml/min per 1.73m
2
 at baseline were randomly assigned to a normal (1.3 g/kg/d) 
or to a low (0.58 g/kg/d) protein diet.  Participants  (n=59, age 50 to 59 years) with more severe 
loss of renal function indicated by a GFR range of 13 to 24 ml/min per 1.73m
2
 were randomly 
assigned to a low (0.58 g/kg/d) or a very low (0.28 g/kg/d) protein diet.  Diet compliance was 
assessed by three-day diet record.  The low protein diet had no effect on GFR in patients with 
moderate renal disease due to PKD, but there was a trend (P=0.06) of the low protein diet 
improving GFR in older participants with more severely compromised kidney function.  
Secondary analyses of the MDRD Study have been undertaken to clarify the effect of protein 
restriction on GFR and onset of ESRD.  Levey et al.45 concluded that the balance of evidence 
was more consistent with the hypothesis of a beneficial effect of protein restriction than with the 
contrary hypothesis of no beneficial effect on chronic kidney disease.  However, no recent 
randomized clinical trials have been conducted on the effects of low protein diets on PKD to 
specifically compare results from the MDRD study on loss of kidney function in ADPKD 
patients.  The absence of a defined amount of protein that delays disease progression while 
meeting protein requirements has led to greater interest in investigating the source of protein on 
PKD. 
PKD and Different Types of Proteins 
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Generally, plant proteins are of lower quality than animal proteins.46  Soy protein is a 
high quality plant protein indicated by rats fed soy protein (20% wt) for 22 months having 
comparable food intake, weight gain, and major organ weights to rats fed the milk protein, casein 
(20% wt).47  To determine the effect of different protein sources on PKD progression, young (age 
28 days) male and female Han:SPRD-cy rats (n=9-10/group) were fed a purified diet  with the 
protein source (20% wt) as either casein or a soy for six weeks.48  PKD progression was 
attenuated in male and female Han:SPRD-cy rats fed the soy protein diet indicated by lower (P< 
0.01) kidney weights, cyst area, and improved renal function measurements of serum creatinine, 
serum urea, and creatinine clearance (Table 2).  The authors suggested that soy protein 
attenuated PKD progression by altering insulin growth factor-1 (IGF-1) which regulates growth 
and GFR.  Additionally, IGF-1 has been reported to increase with disease progression.48  Male, 
but not female, Han:SPRD-cy rats fed soy protein had reduced serum IGF-1, kidney IGF-1 
content compared to casein-fed rats.  Based on the study results, soy protein attenuated PKD 
progression in both male and female Han:SPRD-cy rats.  Male rats were more responsive to 
dietary soy protein due to delayed disease onset in females of this genetic rodent model of PKD.  
However, body weight was reduced in the male rats fed dietary soy protein.  Whether this was 
due to inadequate protein was not addressed. 
Cahill et al.49 exposed offspring to soy protein prenatally and during lactation.  The 
animal model used was the Han:SPRD-cy rats, an animal model of ADPKD.  Rat dams were fed 
a 20% (wt) casein or soy protein diet 2 week prior to mating and throughout pregnancy and 
lactation.  Pups exposed to soy protein in utero and during lactation showed similar effects to 
rats fed soy protein at weaning of reduced (P<0.05) epithelial cell proliferation, renal oxidized 
LDL content, and inflammation (Figure 1).  However, offspring exposed to soy protein in utero 
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and during pregnancy also had reduced renal cyst changes and improved renal function indicated 
by reduced serum urea, serum creatinine, creatinine clearance, and proteinuria (Table 2).  
Furthermore, continued consumption of soy protein after weaning enhanced anti-inflammatory 
effects.  Soy protein was adequate to support growth in the rat pups as evidenced by similar body 
weights to casein at weaning and the end of the study.  The observation of greater beneficial 
effects when soy protein was provided in utero and during lactation has important implication for 
ADPKD, but may be of particular significance to ARPKD since disease onset occurs in utero or 
shortly after birth. 
Aside from soy protein, the effects of other plant proteins on PKD progression have also 
been investigated.  Weanling male Han:SPRD-cy rats were randomly assigned (n=12-14/group) 
to be fed diets containing 17% (wt) casein or plant protein sources consisting of soy, hemp, or 
pea protein for 8 weeks.50  Kidney weight and cyst volume were lower (P< 0.05) in rats fed soy 
and hemp protein compared to rats fed pea protein and casein.  Renal fibrosis was observed in all 
protein groups, however occurrence was less (P< 0.05) in rats fed soy or hemp protein diets.  
Also, serum creatinine concentration was significantly lower in Han:SPRD-cy rats fed the soy 
and hemp protein than the pea protein and casein diets.  Based on the results, different protein 
sources exerted different effects on kidney weight, cysts, fibrosis, and renal function with soy 
and hemp protein showing the highest potential for attenuating PKD progression and severity 
(Table 2).  Additionally, body weight was higher in rats fed soy, pea, and hemp protein 
compared to casein.   
Mechanistic studies of PKD have been conducted in animal models fed soy protein.  
Ogburn et al.51 reported that weanling male Han:SPRD-cy rats fed 20% (wt) soy protein for six 
weeks reduced renal volume (P< 0.001) and cyst volume (P < 0.0001) compared to casein-fed 
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rats (Table 2).  Histological evaluation indicated decreased epithelial cell proliferation, renal 
fibrosis volume, and inflammation indicated by lower (P< 0.0001) interstitial macrophage counts 
(Figure 1).  The renal protective effect was attributed to changes in renal fatty acid composition.  
Higher renal n-6 PUFA, linoleic acid (LA, 18:2n-6) content was observed in rats fed soy protein 
compared to casein-fed rats.  Higher renal LA content was suggested to be due to inhibition of 
Δ6 desaturase enzyme.  Decreased Δ6 desaturase activity prevents conversion of the essential n-6 
PUFA, LA to the long-chain n-6 PUFA, arachidonic acid (ARA, 20:4n-6).  ARA is a substrate 
for the synthesis of the 2-series eicosanoids by cyclooxygenase (COX), which at elevated levels 
are considered to be pro-inflammatory (Figure 2).  However, the proposed mechanism could not 
be confirmed in this study since Δ6 desaturase activity, tissue ARA content, and 2-series 
eicosanoids were not measured. 
Fair et al.52 addressed this by measuring ARA-derived eicosanoids in weanling male 
Han:SPRD-cy rats fed 20% (wt) soy or casein diets.  After 3 weeks, rats fed the soy protein diet 
had lower kidney weights (1.27 g/100 g bwt) than casein-fed rats (1.73 g/100 g bwt).  Also, cyst 
area ratio was significantly lower in Han:SPRD-cy rats fed soy protein diet after 3 weeks of 
feeding.  Renal fibrosis was reduced by 22% after 1 week and 38% after 3 weeks, indicating the 
beneficial effects of longer-duration soy protein feeding (Table 2).  Rats fed the soy protein diet 
had significantly higher renal LA content at week 1 and 3 and prostaglandin E2 (PGE2) which is 
suggested to be protective against disease progression in the early stages of PKD when 
inflammation is low. 
Peng et al.53 measured the activity of the inducible COX-2 enzyme as well as the 2-series 
eicosanoids in male weanling Han:SPRD-cy rats (n= 8-9/diet group) fed a 20 % wt soy protein 
isolate or casein diet.  After 7 weeks, rats fed the soy protein isolate diet had significantly lower 
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kidney COX-2 activity and 2-series eicosanoids compared to casein-fed rats (Figure 2).  The 
results indicated that soy protein reduced inflammation by inhibiting COX-2 activity and this in 
turn, decreased the production of 2-series eicosanoids.  Fatty acids more than protein have been 
studied as regulators of the eicosanoid synthesis.54  Due to its anti-inflammatory properties, n-3 
PUFAs has been investigated as a dietary therapeutic for various diseases including PKD.55  The 
next section reviews the potential role of different lipid sources on PKD progression and 
severity. 
PKD and Dietary Lipids 
 Ogborn et al.56 randomly assigned weanling male and female Han:SPRD-cy rats (n=76-
79) to be fed a standard purified diet with the lipid (7% wt) source consisting of either flaxseed 
oil rich in ALA or corn oil rich in n-6 PUFA, LA for 12 weeks.  Kidney weights were not 
significantly different between diet groups.  However, male rats fed flaxseed oil had lower (P< 
0.05) renal cyst area and inflammation.  Gender differences were indicated by greater renal 
benefits in female Han:SPRD-cy rats.  In addition to lower renal cyst area and inflammation, 
female rats fed flaxseed oil had lower renal epithelial cell proliferation, oxidized LDL tissue 
area, and fibrosis.  Pro-inflammatory responses contribute to disease development and 
progression.  Animal studies have shown that the ARA-derived pro-inflammatory mediator, 
PGE2, is decreased by EPA or docosahexaenoic acid (DHA, 22:6n-3).
54  Female and male 
Han:SPRD-cy rats fed flaxseed oil had increased renal tissue n-3 PUFA deposition, reduced n-6 
PUFA content, and decreased PGE2 release.  Females have been reported to have more efficient 
conversion of ALA to long-chain n-3 PUFAs than males, possibly due to estrogen.57  However, 
whether gender influenced renal long-chain n-3 PUFA composition and PGE2 production in 
Han:SPRD rats fed flaxseed oil was not assessed. 
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To determine whether soy protein and n-3 PUFAs can benefit established PKD, male 
Han:SPRD-cy rats (age 2 months) were fed a combination of different lipid and protein sources 
for 4 months.58  The diets consisted of either soy protein isolate or casein (20% wt) as the protein 
source and corn oil (7% wt) as the lipid source.  To determine the effect of different lipids, a 
flaxseed oil (7% wt) and casein (20% wt) diet was included.  Flaxseed oil is the richest source of 
the n-3 PUFA, ALA;59 whereas, corn oil is rich in the n-6 PUFA, LA.60  As expected, feeding 
flaxseed oil resulted in higher (P=0.003) renal tissue ALA content.  Despite reported inefficient 
conversion of ALA to long-chain n-3 PUFAs,61 renal EPA and DHA content was significantly 
higher in rats fed the flaxseed oil/casein diet compared to the corn oil/casein and corn oil/soy 
protein isolate diets.  Rats fed the flaxseed oil/casein diet also had lower (P=0.01) n-6 PUFA, 
ARA (Figure 2), than rats fed corn oil/casein and corn oil/soy protein isolate diets due to 
competitive inhibition of n-6 PUFA synthesis to ARA by ALA. 
Altered renal tissue fatty acid content reduced renal tubular epithelial cell proliferation 
indicated by lower number of PCNA-positive cells in rats fed flaxseed oil/casein diet (23.3 ± 
1.32 cells/ field) than rats fed corn oil/casein (30.9 ± 0.96 cells/field) and corn oil/soy protein 
(24.4 ± 1.32 cells/ field) diets.  Renal oxidative damage indicated by oxidized LDL tissue area 
was reduced (P= 0.01) in rats fed flaxseed oil/casein and corn oil/soy protein isolate diets 
compared to rats fed corn oil/casein diet.  Rats fed corn oil/soy protein isolate diet had lower 
serum urea nitrogen than rats fed flaxseed oil/casein and corn oil/casein diets.  The study results 
indicated that flaxseed oil rich in the n-3 PUFA, ALA, reduced cell proliferation and oxidative 
damage; whereas, soy protein isolate reduced oxidative damage and improved renal function 
(Figure 1, Table 2).  A flaxseed oil/soy protein isolate group was not included to determine 
whether there were synergistic effects between n-3 PUFAs and soy protein.  Regardless of diet, 
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all animals had similar renal cyst volume and interstitial fibrosis (Table 2, Figure 1) indicating 
late diet intervention had limited benefits on PKD progression.  The results provide important 
information regarding the disease stage when diet therapy should be implemented in order to be 
effective.  Studies investigated the effects of flaxseed oil on PKD used diets consisting of 7% wt 
fat.  Sankaran et al.62 compared feed a high (20% wt) fat to a 7% wt fat diet.  Feeding adult (age 
70 d) male and female pcy mice, a high fat diet for 19 weeks increased kidney weight and serum 
urea nitrogen compared to mice fed a 7% wt.  Feeding weanling male and female pcy mice a 
high fat diet for 8 weeks resulted in higher renal fibrosis volume.  Similarly, feeding male 
weanling Han:SPRD-cy rats fed a high fat (20%) diet for 6 weeks resulted in significantly higher 
renal fibrosis, but also higher renal weight and lower CrCl than rats fed a low fat (5% wt) diet.63  
Based on the results using the pcy mouse and Han:SPRD-cy rat model, a high fat diet worsens 
PKD progression (Table 2). 
The detrimental effects of a high fat diet were modulated by the source of the dietary 
lipid.  Male weanling Han:SPRD-cy rats fed fish oil (menhaden) attenuated the negative effects 
of the high fat diet and even lowered inflammation when fed as the lipid source in high fat diet.  
Feeding fish oil diet rich in n-3 PUFAs, EPA and DHA, lowered kidney weight and cyst volume 
compared to rats fed and cottonseed oil diet rich in n-6 PUFAs or soybean oil diet containing 
ALA.  However, weanling Han:SPRD-cy rats fed the soybean oil diet had the least renal fibrosis.  
Fat type did not affect renal function indicated by no significant differences in serum creatinine 
or CrCl.63  Similarly, weanling male and female pcy mice fed flaxseed oil rich in ALA mitigated 
renal fibrosis in mice fed high fat (20% wt) diet.62  In contrast, feeding algal oil rich in DHA, 
increased kidney weight, renal cyst volume, serum urea nitrogen, and showed failure to thrive 
indicated by reduced body weight (Table 2).  Weanling pcy mice fed (10% wt) fish oil 
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throughout the lifespan resulted in higher proteinuria (P=0.04) and reduced (P<0.05) survival 
compared to sunflower seed oil rich in n-6 PUFA, LA in male, but not female mice (Table 2).64  
These results suggest the potential benefit of fat source rich in EPA and/or DHA may be limited 
to the early stages of PKD progression. 
Sankaran et al.62,65 investigated potential mechanism of actions of different fat sources.  
The fat sources consisting of corn oil and cotton oil rich in the n-6 PUFA, LA, flaxseed oil rich 
in the n-3 PUFA, ALA, fish (menhaden) oil rich in long-chain n-3 PUFAs, EPA and DHA, and 
DHA-rich algal oil were fed for 8 weeks.  CD1-pcy/pcy mice and Han:SPRD-cy rats fed 
EPA/DHA-rich fish oil and DHA-rich algal oil up-regulated COX-2 gene expression compared 
to LA-rich corn oil and cotton oil diets (Figure 2).  However, feeding rats flaxseed oil diet rich in 
ALA had no significant effect on COX-2 gene expression.  Results indicated that supplementing 
long-chain n-3 PUFAs up-regulated COX-2 gene expression in the kidneys.  In models of 
chronic renal disease, renal injury increases COX-2 gene expression and activity; whereas, in 
models of renal cystic disease COX-2 expression is reduced, but activity is increased.66
,67  
Therefore, the authors suggested that increased renal COX-2 expression by diets containing EPA 
and DHA or DHA alone reflected a decrease in renal COX-2 activity.  EPA, but not ALA, is a 
direct substrate for COX-2 and DHA can regulate COX-2 through the transcription factor, 
nuclear factor kappaB.68  Synthesis of the less potent 3-series eicosanoids through the COX 
pathway can reduce inflammatory responses that contribute to disease development and 
progression.54  However, the products of COX-2 enzymes were not determined in this study.   
Worsened PKD progression in weanling pcy rats fed DHA-rich algal oil was suggested to 
be due to increase renal long-chain n-3 PUFA content at the expense of n-6 PUFAs that resulting 
in inadequate tissue n-6 PUFA content as well as the potential of higher oxidation.62  Similarly, 
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feeding fish oil to pcy mice that contained DHA (11 mol%) as well as EPA (22 mol%) also 
worsened PKD progression.  Yamaguchi et al.69 investigated n-3 PUFA, EPA.  Male (n=12) and 
female DBA/2FG-pcy mice (n=12) age 50-58 days were fed diets containing sunflower seed oil 
rich in n-6 PUFA, LA or MaxEPA, an EPA-enriched fish oil concentrate, for 60 days.  Both 
male and female mice fed the MaxEPA diet had significantly lower mean kidney weights and 
tubular dilation of the renal cortex and medulla, but there was no effect on renal function 
indicated by no significant differences in blood urea and serum creatinine levels.  Male, but not 
female, mice fed the MaxEPA diet had significantly decreased renal cyst area.  Feeding male 
mice the MaxEPA diet increased renal n-3 PUFA and decreased n-6 PUFA content.  The effect 
of diet on renal tissue fatty acid composition was not evaluated in female mice to determine 
whether this was a factor.  Instead, the less pronounced renal effects of EPA feeding on female 
DBA/2FG-pcy mice were attributed to slower PKD progression compared to males. 
Higashihara et al.70 determined the efficacy of n-3 PUFA supplementation on PKD in 
human subjects.  In this prospective study, ADPKD patients were randomly divided into a 
treatment group (n=20, age 47.5 +12.5, n=14 males and n=6 females) provided EPA capsules 
(2.4 g/day EPA ethyl ester) for 2 years and an untreated group (n=20, age 46.8 +11.4, n=15 
males and n=6 females) asked not to take any EPA-rich supplements.  Results showed no 
significant differences between the dietary treatment groups for kidney volumes measured by 
computerized tomography or creatinine clearance and urinary albumin.  The results contrasted 
animal studies reporting beneficial effects of n-3 PUFA supplementation on PKD.  A major 
limitation of this study was the small sample size and therefore, conclusions regarding the 
efficacy of n-3 PUFA efficacy were problematic.  In most animal studies n-3 PUFA 
supplementation occurred at weaning (Table 2); whereas, n-3 PUFA supplementation for 
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ADPKD patients occurred in the more advanced disease stage.  Additionally, individuals 
provided EPA capsules had higher erythrocyte (P<0.001) EPA content, but DHA content was 
decreased (P<0.01), suggesting inefficient conversion.  Results obtained from rodent models 
should be carefully evaluated when extrapolating effects to humans since conversion of EPA and 
DHA is more efficient in mice and rats than in humans.71 
Other fatty acids being investigated are the conjugated linoleic acids (CLAs).  Most 
studies have use trans-10-cis-12 and the cis-9-trans-11 CLA isomers.  Anti-inflammatory 
mechanisms attributed to CLAs include: 1) competition with LA for desaturase and elongase 
enzymes to reduce tissue ARA content, 2) inhibition of phospholipase A2 enzyme that release 
tissue ARA, and 3) inhibition of COX-2 expression.72
,73  In addition to inflammation, the CLA 
cis-9-trans-11 isomer has been associated with anti-proliferative effects of the cysts.74 
Ogborn et al.75 fed weanling male Han:SPRD-cy rats a standard purified diet consisting of 
corn oil (7 % wt) or corn oil (5.33% wt) supplemented with CLA (1.67% wt) for 8 weeks.  CLA 
supplementation had no significant effect on cyst formation or serum creatinine (Table 2), but 
reduced inflammation indicated by lower macrophage infiltration (P< 0.001), lower (P= 0.022) 
renal PGE2 content, and reduced renal interstitial fibrosis (P=0.03) (Figure 1).  Rats provided the 
CLA supplemented diet had significantly reduced renal tissue phospholipase A2 protein level, 
COX-2 protein level and activity, and lower steady-state TXB2, PGE2, and 6-keto-PGF1α 
(Figure 2).76  Based on the results, CLA supplementation attenuated the later stages of PKD by 
reducing the synthesis of ARA-derived pro-inflammatory eicosanoids. 
To investigate gender differences, Ogborn et al.77 fed weanling male (n=47) and female 
(n=54) Han:SPRD-cy rats a diet consisting of corn oil (7% wt) or corn oil supplemented with 1 
or 2 % (wt) CLA for 12 weeks.  Feeding both male and female rats diets supplemented with 
20 
 
CLA increased (P=0.001) renal CLA content.  However, female rats showed a dose-dependent 
response in renal (P=0.005) CLA cis-9-trans-11 content.  Both male and female Han:SPRD-cy 
rats provided diets supplemented with CLA had lower (P< 0.001) renal epithelial cell 
proliferation.  Female rats provided CLA also showed a dose-dependent decrease in oxidative 
damage, inflammation, and fibrosis.  CLA acts as a ligand for the transcription factor peroxisome 
proliferator-activated receptor gamma (PPARγ) which plays important roles in regulating cell 
proliferation, inflammation, and fibrosis.78  However, in this study was no significant effect of 
CLA supplementation on PPARγ activation in either gender.  Also, CLA supplementation 
increased serum creatinine concentration in female rats suggesting a possible decline in renal 
function.  Therefore, more studies are needed before CLA supplementation can be recommended 
as a dietary treatment for PKD. 
Based on the results of the animal studies, different lipid sources exert different effects.  
CLAs and long-chain n-3 PUFAs altered COX-2 enzyme activity; whereas, ALA-rich flaxseed 
oil had no significant effect on COX-2 enzyme activity.  However, weanling male Han:SPRD-cy 
rats fed standard purified diet supplemented with whole flaxseed (10% wt) for eight weeks had 
reduced (P<0.05) renal cyst volume, inflammation, fibrosis, and improved kidney function79 
(Table 2, Figure 1).  The results suggested that flaxseed has other dietary components with the 
potential to attenuate PKD progression and severity.  Flaxseed oil and other plant oils are rich in 
the antioxidant, α-tocopherol.80 Antioxidants can prevent tissue injury that promotes PKD 
progression and severity.  Reduced endogenous antioxidant enzymes and increased oxidative 
stress has been reported in Han:SPRD-cy rat and C57BL/6J-cpk mice models of PKD.81
,82  
Therapeutic drugs with antioxidant properties have been reported to attenuate renal cystic 
diseases in rat and mouse models.83
,84  In human studies, increased plasma lipid peroxidation and 
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reduced endogenous antioxidant enzyme activity has been observed in individuals with inherited 
ADPKD85 as well as in individuals with spontaneous renal cysts.86  Men with ADPKD or 
spontaneous renal cysts have more rapid progression to ESRD than woman, indicating gender 
plays an important role in PKD progression and severity.87
,43  Higher renal α-tocopherol content 
in female Hans:SPRD-cy rats suggests that tissue differences in vitamin E may be responsible for 
slower PKD progression in females.88  Torres et al.88 provided weanling male (n=6-7) and female 
(n=4-10) Han:SPRD-cy rats a vitamin E deficient diet or diets supplemented with 65 IU or 
10,000 IU α-tocopherol for 8 weeks.  Feeding diets supplemented with α-tocopherol increased 
kidney α-tocopherol content, but there were no significant effects on kidney weight, cyst index, 
inflammation, and kidney function markers, plasma creatinine and urea (Table 2, Figure 1).  Due 
to the absence of significant beneficial effects, vitamin E supplementation is not being 
recommended as a treatment for PKD.  Absence of antioxidant effects on PKD may be because 
cyst pathogenesis is regulated by multiple pathways.  Phytochemicals and phytoestrogens have 
antioxidant as well as anti-proliferative, ant-inflammatory, and hormonal properties89 and 
therefore, may be effective therapeutic agents. 
PKD and Phytoestrogens and Phytochemicals 
Phytoestrogens and phytochemicals effect cellular signaling and therefore, can alter 
developmental and physiological events.90  Soy protein and soy products are the major sources of 
the phytoestrogen, isoflavones.90  Ogborn et al.91 fed weaning male Han:SPRD-cy rats diets 
consisting of 20% (wt) casein or soy protein diets with high (3.62 mg/g protein) or low 
isoflavone (0.11 mg/g protein) content for 8 weeks.  Rats fed the soy protein-based diets had 
similar effects on inflammation and renal function.  However, rats fed the soy protein diet high in 
isoflavones showed less renal oxidative damaged; whereas, rats fed the soy protein diets low in 
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isoflavones showed the greatest reduction in relative renal weight, cystic changes, and epithelial 
proliferation.  Based on the results, the beneficial effects of soy containing isoflavones on PKD 
differed depending on the dose (Table 2, Figure 1). 
To determine whether the renal effects of isoflavones were independent of soy protein, 
Tomobe et al.82 fed young (age 60 days) male pcy mice a casein diet (25 g/100 g diet) with or 
without the isoflavone, genistein (0.05 g/100 g diet).  Genistein supplementation for 60 days had 
no significant effect on kidney weight, water content, and cyst volume (Table 2).   The study 
results suggested that dietary factors other than phytoestrogens were responsible for the 
beneficial effects of soy protein.  Both studies investigating the effects of dietary phytoestrogens 
used males.  However, gender differences should be considered since phytoestrogens are non-
steroidal plant-derived compounds with structural similarity to endogenous estrogens and 
therefore, have the ability to exert weak estrogenic or anti-estrogenic effects.92 
Flaxseed is the richest source of secoisolariciresinol diglycoside (SDG) which is the 
precursor of mammalian lignans.93  Ogborn et al.94 fed weanling male and female Han:SPRD-cy 
rats (n=76-79) diets supplemented with SDG (20 mg/kg diet) or no SDG for 12 weeks.  Male and 
female rats fed SDG diets had no significant effect on kidney weight, cysts, and fibrosis, but 
renal inflammation was reduced (P<0.05) (Table 2, Figure 1).  Female, but not male, Han:SPRD-
cy rats fed a diet supplemented with SDG reduced oxidative damage indicated by lower oxidized 
LDL renal tissue area (Figure 1).  Estrogen has been reported to have antioxidant effects and to 
suppress inflammation.95  Based on the study results, dietary phytoestrogens effects differed 
depending on gender with more beneficial effects on PKD in female than male rats. 
Phytoestrogens also act on several pathways involved in cytogenesis such as AMP-
activated protein kinase, mitogen-activated protein kinase (MAPK), and peroxisome proliferator-
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activated receptor gamma (PPARγ).90  However, few studies have investigated the potential of 
phytoestrogens to attenuate PKD by inhibiting these pathways.  Tumeric is a spice used as an 
ingredient in curry.  The main biologically active phytochemical compound in turmeric is the 
yellow pigment, curcumin.  Curcumin has been reported to show beneficial effect against 
inflammatory diseases and to be safe for human consumption.96  Gao et al.97 used murine 
embryonic and Madin-Darby canine kidney cells as a cyst model to explore mechanisms of cyst 
inhibition.  Cells treated with curcumin reduced cyst epithelial proliferation by inhibiting the 
Ras/MAPK signaling pathway.97  To determine the potential therapeutic effects of curcumin in 
vivo, a Pkd1-deletion mouse model of ADPKD (n=5, age 49 days, gender not provided) were fed 
a diet supplemented with 1% (wt) or no curcumin.  Mice provided curcumin for 11 weeks 
showed beneficial effects on the early stages of PKD indicated by reduced cell proliferation 
index, cystic index, and kidney weight/body weight ratio (Table 2, Figure 1).  Mice that 
continued to be fed curcumin for 15-17 weeks had postponed renal failure.98  Together these 
studies provided evidence that phytochemicals inhibited PKD progression and severity through 
multi-pathways.  Compounds currently under investigation in clinical trials mainly act on single 
pathways although multiple pathways are involved in PKD.98  Consequently, this requires high 
doses which increasing the risk of side effects.  By acting simultaneously on various PKD-
related pathways, diet can provide a successful and safer therapeutic option. 
Various dietary components were reported to attenuate PKD progression and severity 
(data summarized in Table 2).  Currently, low protein diets are recommended to PKD patients.  
However, data from animal and human studies are inconsistent and the benefits and safety of low 
protein diets for PKD remain controversial.  Instead, the type of dietary protein may be of 
importance.  In animal studies soy protein consumption attenuated the early stages cyst 
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pathogenesis indicated by reduced epithelial cell proliferation and apoptosis as well as the later 
stages by reducing oxidative damage, inflammation, and fibrosis (Figure 1).  Aside from dietary 
proteins, there are an increasing number of studies investigating the role of the amount of dietary 
lipids and fat type on PKD.  Supplementation of n-3 PUFAs attenuated epithelial cell 
proliferation, oxidative damage, inflammation, and fibrosis.  However, renal effects differed 
depending on whether the type of n-3 PUFA consumed was ALA, EPA or DHA.  Dietary n-3 
PUFAs has the potential to influence multiple steps in PKD pathogenesis, but studies have 
mainly focused on altering tissue fatty acid composition and eicosanoid metabolism.  CLA, 
another class of fatty acids, also showed beneficial effects on PKD.  However, potential safety 
concerns were raised based on the observation of reduced kidney function in female Han:SPRD-
cy rats.  Flaxseed SDG, soy isoflavones, and curcumin are other dietary compounds that showed 
promise for attenuating cystogenesis.  However, more research is needed to confirm the efficacy 
of these dietary compounds on PKD. 
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Table 1. Characteristics of genetic animal models of polycystic kidney disease commonly used to study therapeutic inventions 
Model Gene Mutation Genotype Human Phenotype Equivalent Encoded Protein 
pcy mouse NPHP3 Autosomal Recessive Autosomal Dominant Nephrocystin 
cpk mouse Cys1
cpk
 Autosomal Recessive Autosomal Recessive Cystin 
bpk mouse Bicc1
bpk
 Autosomal Recessive Autosomal Recessive mRNA-binding protein 





 Autosomal Recessive Autosomal Recessive Polaris 
Han:SPRD-cy Pkdr1 Autosomal Dominant Autosomal Dominant SamCystin 
pck rat Pkhd1 Autosomal Recessive Autosomal Dominant/Recessive Fibrocystin 
Adaptation from Torres et al. (2007)5 and Guay-Woodford
89
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Table 2.  The effect of different diet components on kidney weight, cysts, and function 
Authors                  Dietary Study        Results 
                         Low Protein 
Tomobe et al. (1994)35  male pcy mice age 70 d 
low protein (6 g/100g diet) for 3.5 months 
 kidney weight 
 kidney cyst area 
NS kidney function 
Ogborn and Sareen. (1995)38 male Han:SPRD-cy rats age 60 d 
low protein (8 g/100g diet) for 4 months 
 relative kidney 
volume 
 kidney cyst volume 
 kidney function 
Choukroun et al. (1995)43 ADPKD patients (n = 109) age 46.1 ± 0.9 years 
0.7-1.2 g/kg/d protein for 6.7 ± 0.3 years 
 
NS kidney function 
Klahr et al. (1995)44 ADPKD patients (n = 41) age 40-49 years 
0.58 g/kg/d protein for 2.2 years 
ADPKD patients (n = 59) age 50-59 years 
0.58 g/kg/d protein for 2.2 years 
NS kidney function 
 
 trend (P = 0.06) 
kidney function  
      
                       Types of Protein 
Aukema and Housini 
(2001)48 
male/female Han:SPRD-cy rats age 28 d 
20% wt soy protein for 6 weeks 
 kidney weight
 kidney cyst area 
 kidney function 
Cahill et al. (2007)49 Han:SPRD-cy rats offspring in utero/lactation  
20% wt soy protein 
 kidney cyst changes 
 kidney function 
Aukema et al. (2011)50 male Han:SPRD-cy rats age 21 d 
17% wt soy protein and hemp protein 
 kidney weight 
 kidney cyst volume 
 kidney function 
Ogborn et al. (2000)99 male Han:SPRD-cy rats age 21 d 
20% wt soy protein for 6 weeks 
 kidney volume 
kidney cyst volume 
Fair et al. (2004)52 male Han:SPRD-cy rats age 21 d 
20% wt soy protein for 1 or 3 weeks 
 relative kidney weight 
 kidney cyst area ratio 
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Dietary Lipids and Vitamin E 
Ogborn et al. (2006)94 male/female Han:SPRD-cy rats age 21 d 
7% wt flaxseed oil for 12 weeks 
NS kidney weight 
 kidney cyst area 
Sankaran & Bankovic 
(2007)62 
male Han:SPRD-cy rats age 2 months 
7% wt flaxseed oil for 4 months 
NS kidney cyst volume 
 
Yamaguchi et al. (1990)69 male/female DBA/2FG-pcy age 50-58 d 
EPA supplement for 60 days 
 kidney weight 
 renal tubular dilation 
 kidney cyst area (males) 
NS kidney function 
Higashihara et al. (2008)70 male/female ADPKD patients (n = 6-14) 
age 47.5 ± 12.5 years 
2.4 g/d EPA supplements for 2 years 
NS kidney volume 
NS kidney function 
Ogborn et al. (2003)75 male Han:SPRD-cy rats age 21 d 
1.67% wt CLA for 8 weeks 
NS kidney cysts 
NS kidney function 
Ogborn et al. (2008)77 male/female Han:SPRD-cy rats age 21 d 
1 or 2% wt CLA for 12 weeks 
 kidney function (females) 
Ogborn et al. (1999)79 male Han:SPRD-cy rats age 21 d 
10% wt flaxseed for 8 weeks 
 kidney cyst volume 
 kidney function 
Torres et al. (1998)100 male/female Han:SPRD-cy rats age 21 days 
65 IU or 10,000 IU α-tocopherol for 8 weeks 
NS kidney weight 
NS kidney cyst index 
NS kidney function 
Phytoestrogens/Phytochemicals 
Ogborn et al. (2010)91 male Han:SPRD-cy rats age 21 d 
soy protein + isoflavones (3.62 or 0.11 mg/g 
protein) for 8 weeks 
 relative kidney 
weight 
kidney cyst changes 
kidney function 
Tomobe et al. (1998)101 male pcy mice age 60 d 
genistein (0.05 mg/100 g diet) for 60 d 
NS kidney weight 
NS kidney cyst volume 
Ogborn et al. (2006)56 male/female Han:SPRD-cy rats age 21 d 
SDG (20 mg/kg diet) for 12 weeks 
NS kidney weight 
NS kidney cysts 
28 
Leonard et al. (2011)98 Pkd1-deletion mice age 49 d 
1% wt curcumin for 11 or 15-17 weeks 
 relative kidney weight 
kidney cystic index 
 kidney function with 
     longer feeding 




Figures 1.  The role of dietary components on cyst pathogenesis in polycystic kidney disease.  
Abbreviations are (-) inhibition; CLA, conjugated linoleic acid; SDG, secoisolariciresinol 
diglycoside. 
 
Figure 2.  The role of dietary components on omega-6 and omega-3 polyunsaturated fatty acids 
and eicosanoid production in polycystic kidney disease.  Abbreviations are (-) inhibition; (+) 
simulation; n-6 PUFA, omega-6 polyunsaturated fatty acids; n-3 PUFA, omega-3 
polyunsaturated fatty acids; LA, linoleic acid; ALA, alpha-linolenic acid; ARA, arachidonic 
acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; COX-2, cyclooxygenase-2,  
PGE2, prostaglandin E2; TXB2, thromboxane B2; 6-keto PGF1α, 6-keto prostaglandin F1 alpha; 
CLA, conjugated linoleic acid; SDG, secoisolariciresinol diglycoside. 
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1.2.  PKD Complications 
Bone Loss 
Effective therapies promote improvement at the disease site and related disease 
complications as well as reduce the risk of side-effects.  As kidney function degrades, it is 
possible for minerals to be excreted in the urine.  Excessive mineral losses may eventually 
compromise bone mineral content and decreased bone health. Epidemiological studies have 
demonstrated greater incidence of bone fractures in ESRD patients.
102
  PKD is a major cause of 
ESRD.  In 2008, 547,982 patients in the United States were diagnosed with kidney disease and 
received treatment (i.e. dialysis or kidney transplant) for ESRD.2  Of those patients, 
approximately 22% of all ESRD cases were due to PKD.2  Also, several drugs used to treat PKD 
has reported side effects of bone loss.21 
Bone Morphometry and Function 
Bone biology and metabolism was extensively reviewed in Lukas 2010.103 Briefly, the 
skeletal system functions to support the body structurally, store minerals and lipids, produce 
blood cells, protect soft tissues, and act as levers to change direction and magnitude of the forces 
from skeletal muscles.  Several segments make up the long bone. The diaphysis is the bone’s 
shaft and the epiphyses are the proximal and distal ends of the bone.104  In a mature bone, the 
metaphyses are where the diaphysis joins the epiphyses. In a growing bone, the metaphyses 
include the epiphyseal plate. A tough sheath of dense irregular connective tissue called the 
periosteum covers the bone. Cartilage covers the bone where the bone forms a joint with another. 
The marrow cavity (i.e., medullary cavity) is the space within the diaphysis that contains bone 
marrow.  The microarchitecture of the bone consists of epiphyses containing spongy or 
trabecular bone. Trabecular bone has a honeycombed structure and has a thin covering of cortical 
5 
bone.104  In cortical bone, calcium phosphate [Ca3(PO4)2] accounts for almost two-thirds of the 
weight of the bone.104  Calcium phosphate interacts with calcium hydroxide, [Ca(OH)2] to form 
crystals of hydroxyapatite, [Ca10(PO4)6(OH)2]. The hard and brittle hydroxyapatite crystals are 
stored in the bone matrix and can withstand compression, but break when bent or twisted.104 In 
contrast, collagen fibers in the bone matrix are flexible and can tolerate twisting or bending, but 
not compression.104 The combination of the hydroxyapatite crystals and collagen fibers forms a 
strong bone that is somewhat flexible and highly resistant to fracture. 
Bone turnover markers 
There are three categories of bone turnover markers: enzymes/proteins that are secreted 
by cells involved in remodeling process, breakdown products generated in the resorption of old 
bone, and byproducts produced during the synthesis of new bone.
105
  Serum osteocalcin is 
commonly used as an indicator of bone formation (osteoblast activity).  Osteocalcin is a bone-
specific protein released into the blood during new matrix formation.
106
  Osteoblasts are rich in 
alkaline phosphatase, however the function of this enzyme is unknown.
105
 Osteoblast as well as 
osteoclast activity regulate bone mass.
106
  Bones weaken when osteoclasts remove bone faster 
than osteoblasts deposit bone.
104
 Urinary deoxypyridinoline (DPD) is the primary? clinical 
function marker that is used to determine system bone resorption.
102
  Increased levels of DPD in 
the urine indicate resorption is occurring within the bone.   
Bone Mineralization, Microarchitecture, and Strength 
Demineralization and the breakdown of collagen in the bone matrix results in bone 
loss.107  Cortical mineralization can be determined by using dual energy x-ray absorptiometry 
(DEXA) to measure bone mineral density (BMD), bone mineral content (BMC) and bone 
mineral area (BMA).  BMD represents a measurement of the bone mass per cm2, BMC 
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represents the mass of the bone, and BMA represents the area of bone occupied by minerals. 
Decreased BMD and BMC increase bone fragility and susceptibility to fracture.108 
Bone architecture can be determined using micro-computed tomography (μCT). 
Trabecular bone volume to total tissue volume ratio (BV/TV) is the trabecular fraction of bone in 
the sample, trabecular number (TbN) is the number of trabeculae per mm of bone, trabecular 
thickness (TbTh) represents the mean diameter of the trabeculae, trabecular separation (TbSp) is 
the mean size of the intertrabecular spaces, connectivity density (CONN) is a quantified 
measurement of elasticity, and structure model index (SMI) characterizes the type of structure of 
the sample (rod-like, plate-like, or mixed structures). High values for BV/TV, TbN, TbTh and 
CONN correlate with a strong bone. High values for TbSp indicate a weak bone. A bone having 
more rod-like structures is weaker than bone having more plate-like structures.109  For an ideal 
plate structure, SMI is close to 0 and for an ideal rod structure the value is 3.  Low bone 
mineralization and microarchitecture decreased bone strength is defined as susceptibility to 
fracture.110 
 Bone fragility is defined by biomechanical parameters. These parameters include: 
strength, brittleness, work to failure, and stiffness.110  A force- displacement curve generated by 
strength testing used to calculate bone biomechanical parameters. 
Dietary Treatment of PKD Related Bone Loss 
To our knowledge few studies have few studies have investigated the role of diet on bone 
in PKD.  In the ADPKD rat model, Hans:SPRD-cy rats fed 5% wt flaxseed oil rich in ALA for 8 
weeks had no significant effect on whole body BMC and BMD.111  However, growing female 
Hans:SPRD rats, a model of ADPKD, fed 7% wt flaxseed oil rich in n-3 PUFA, ALA, before the 
onset of disease and continuing for 12 weeks, lengthened the femur compared to rats fed corn oil 
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low in ALA.21  Early diet management by optimizing bone health during the growth stage can 
potentially minimize bone loss due to renal dysfunction and ERSD at an early age in PKD 
patients.112,113  Dietary fats may affect bone by altering Ca balance.  Kruger et al. 2005114 reported 
that young (age 5 weeks) male Sprague-Dawley rats fed 5% tuna oil g/kg diet had significantly 
higher Ca absorption and decreased urinary Ca compared to the rats fed evening primrose oil. 
The authors suggested that cell membrane saturation reduced Ca absorption and decreased cell 
membrane saturation due to n-3 PUFA consumption resulting in increased Ca absorption and 
decreased urinary Ca loss.  Claassen et al115 fed growing (age 21 days) male Sprague-Dawley rats 
different ratios of γ-LA:EPA. Ratio of 3:1 of γ-LA:EPA decreased Ca excretion and led to rats 
with higher (P<0.05) bone Ca content compared to the control ratio of 3:1 of LA:ALA. Feeding 
healthy growing female Sprague-Dawley rats SPI enhanced bone mineral content (BMC) and 
bone mineral density (BMD) compared to casein.19  It remains unknown if soy protein isolate can 
improve bone health in female pck rats. 
Aside from renal related complication, an extra-renal complication of PKD is that cysts 
are not confined to the kidney and may form in various organs.  The most common extra-renal 
cyst manifestation of PKD is cysts in the liver.6   
Liver Anatomy and Physiology 
Liver anatomy and physiology has been extensively described in Baynes and 
Dominiczak.116  Briefly, the human liver, comprised of four major lobes, is the largest solid organ 
in the body (secondary to skin) and is located in the upper right section of the abdominal cavity.  
The liver is known to perform a variety of functions, but a main function of the liver is nutrient 
and drug metabolism.  The liver receives all products of digestion by venous blood via the 
hepatic portal vein from the intestine for metabolism.   
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Lipid digestion, absorption, transport 
 Triglycerides comprise nearly 90% of all lipid intake in the diet.116  The other lipid 
components ingested in the diet consist of cholesterol, phospholipids, and free fatty acids.  
Following dietary intake of triglycerides and cholesterol, the lipids are hydrolyzed to allow for 
transport throughout the body.  In the small intestine, triglycerides are broken down to free fatty 
acids, re-esterified, and packaged into chylomicrons for transport in the lymph to other 
peripheral tissues to be used for energy or stored?.   
Lipid Metabolism 
Lipid metabolism has been extensively reviewed by Baynes and Dominiczak. 116  Briefly, 
triglycerides, cholesterol, and phospholipids are synthesized in the liver via de novo synthesis. 
After synthesis lipids may be transported from the liver by lipoproteins.  Very low-density 
lipoproteins (VLDLs) are synthesized in the liver and are used to transport triglycerides from the 
liver to the adipose and skeletal muscle for storage and energy.  Endogenous cholesterol is 
synthesized in the liver and transported in the plasma by other lipoproteins.  Cholesterol is 
transported from the liver to other tissues as  low-density lipoproteins (LDL).  High-density 
lipoproteins (HDL) bring excess cholesterol from other tissues back to liver to be excreted as 
bile.   
Nonalcoholic fatty liver disease (NAFLD) is a condition that has recently become more 
prevalent in the United States.  NAFLD is the most common form of liver dysfunction and is a 
result of increased hepatic lipid accumulation.117  The main cause of NAFLD is increased 
accumulation of triglycerides stored in the liver, leading to increased lipid content within the 
hepatocytes.  NAFLD can promote steatosis, liver inflammation, fibrosis, and eventually 
9 
cirrhosis.  Increased inflammation and fibrosis of the hepatic tissue are often associated with 
mortality.117  
Serum Biomarkers of Liver Function 
There are several measurements used to monitor the status of liver function and ensure 
proper regulation of lipid metabolism.116  Liver function markers are of importance in both in 
clinical and research settings.  Serum markers of hepatic function include: cholesterol, gamma-
glutamyl transferase, alanine aminotransferase, and albumin.
118
  The most sensitive enzymatic 
clinical indicator of hepatobiliary disease is gamma-glutamyl transferase (GGT).  Although GGT 
is present in both the kidneys and the liver, the serum enzyme GGT assay originates only from 
the liver.  Although GGT levels are highest following a hepatic obstruction, any form of liver 
disease will cause GGT levels to become elevated, making it very reliable serum assay.  Another 
clinical marker of liver function is alanine aminotransferase (ALT).  Although this serum marker 
is not as sensitive as GGT, liver damage causes an increase in the serum ALT enzyme.  Serum 
albumin is also a marker of liver function since albumin is produced in the liver.  Decreased 
serum albumin levels are often indicative of acute or chronic liver damage.  Serum cholesterol is 
generally used as a screening tool for cardiovascular risk, but can also indicate if the liver is 
properly excreting and transporting cholesterol to the tissues.   
Polycystic Liver Disease 
Polycystic liver disease (PLD) is characterized by the presence of fluid-filled sacs 
throughout the epithelium of the hepatic tissue.  PLD is the most common complication 
associated with PKD.6  Furthermore, females with PKD experience more extensive liver cyst 
progression than males.  Individuals with PKD that experience cysts in the liver may also 
eventually experience altered liver function.
118
  Although no studies have examined the role of 
10 
diet in PLD, diet may offer a potential treatment to slow liver cyst progression.  PLD has similar 
pathogenesis of PKD, therefore dietary treatment that has been shown to improved PKD 
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2.0 Study Objectives 
Study 1  
Objective: To investigate the role of SPI and/or n-3 PUFAs on PKD progression and severity in 
female pck rats. 
Hypothesis:  The supplementation of SPI and n-3 PUFAs will reduce renal inflammation and 
fibrosis and therefore, delay PKD progression and reduce renal cyst severity in female pck rats. 
Study 2  
Objective: To determine the whether feeding growing female pck rats SPI and/or n-3 PUFAs 
can enhance bone morphometry, mineralization, microarchitecture, and strength. 
Hypothesis:  Feeding SPI and n-3 PUFAs will enhance bone morphometry, mineralization, 
microarchitechture, strength, and overall bone health in female pck rats by increasing femur and 
tibial BMD and BMC. 
Study 3 
Objective: To determine the role of SPI and/or n-3 PUFAs on PLD progression and severity in 
female pck rats. 
Hypothesis:  SPI and n-3 PUFA supplementation will increase hepatic EPA and DHA tissue 
content and this in turn will reduce hepatic inflammation and PLD progression in female pck 
rats.  
 
Overall Hypothesis:  Feeding SPI and n-3 PUFAs will reduce PKD inflammation, progression, 
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3.1.  Abstract 
Polycystic kidney disease (PKD) is an incurable genetic disorder characterized by 
multiple benign cysts.  As PKD progresses cyst growth increases kidney volume, decreases renal 
function, and may eventually lead to end stage renal disease.  Feeding soy protein isolate reduced 
cyst proliferation and growth in a PKD rat model.  Omega-3 polyunsaturated fatty acids (n-3 
PUFAs) have anti-inflammatory actions.  Therefore, diet therapy can offer a potentially 
efficacious, safe, and cost-effective strategy for treating PKD.  The objective of this study was to 
investigate the role of soy protein and/or n-3 PUFAs on PKD progression and severity in the rat 
model of autosomal recessive PKD (ARPKD).  We hypothesized that to anti-proliferative and 
anti-inflammatory actions associated with soy protein and n-3 PUFA supplementation will 
attenuate PKD progression in female PCK rats.  Young (age 28 d) female PCK rats were 
randomly assigned (n=12/group) to diets consisting of casein + corn oil (Casein + CO), casein + 
soybean oil (Casein + SO), SPI + soybean oil (SPI + SO) or SPI + 1:1 soybean/salmon oil (SPI + 
SB) for 12-weeks.  Feeding different protein and lipid sources had no significant effect on 
relative kidney weight.  Histological evaluation showed no significant differences in cortical or 
medullary cyst size, interstitial inflammation, and fibrosis among diet groups.  However, rats fed 
SPI+ SB diet had cortical cyst obstruction and the highest (P< 0.01) serum blood urea nitrogen 
concentration.  Rats fed SPI+SB diet had the highest (P< 0.001) renal DHA, but there were no 
significant differences in renal tissue inflammatory and proliferation gene expression among the 
diet groups.  Based on the results, dietary soy protein and/or n-3 PUFAs did not attenuate disease 
progression or severity i the female PCK rat model of ARPKD. 
Keywords: rat, polycystic kidney disease, n-3 PUFAs, soy protein, diet therapy
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3.2.  Introduction 
Polycystic kidney disease (PKD) is a genetic disorder characterized by multiple benign 
cysts derived from the epithelial lining of the nephron [1].  As PKD progresses cyst growth 
increases kidney volume, reduces renal function, and eventually leads to end stage renal disease 
[2].  In 2008, 547,982 patients in the United States were diagnosed with kidney disease and 
received treatment (i.e. dialysis or kidney transplant) for end stage renal disease at a cost of 
39.46 billion dollars [3].  Of those patients, approximately 22% of all end stage renal disease 
cases were due to PKD [3]. 
The two main forms of PKD are autosomal dominant polycystic kidney disease 
(ADPKD) and autosomal recessive polycystic kidney disease (ARPKD).  In ADPKD, renal 
disease onset occurs in early adulthood while ARPKD has infantile renal disease onset [4].  The 
poor prognosis associated with PKD has resulted in studies investigating various therapeutic 
strategies to attenuate disease progression.  Diet therapy offers a potentially efficacious, safe, and 
cost-effective strategy for treating PKD.  Studies have examined the role of different protein and 
lipid sources as a diet strategy for decreasing PKD progression and severity using the 
Hans:SPRD-cy rat, a non-orthologous animal model of ADPKD [5,6]  Omega-3 polyunsaturated 
fatty acids (n-3 PUFAs) have been reported to have anti-inflammatory actions mediated through 
alterations in membrane composition, gene expression, and eicosanoid production [7,8]  Male 
Han:SPRD-cy rats fed diets supplemented with n-3 PUFAs significantly decreased renal 
inflammation and damage [9]. 
Protein consumption exceeding 0.8 g/kg body weight has been suggested to negatively 
affect PKD by causing higher renal perfusion and kidney hyperfiltration of the already 
compromised nephron [10].  However, protein restriction may be associated with risk of protein 
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malnutrition, particularly for ARPKD characterized by early onset that includes rapid growth 
stages.  The absence of a defined amount of protein that delays disease progression while 
meeting protein requirements has led to greater interest in investigating the source of protein on 
PKD [6].  Feeding soy protein isolate has been shown to reduce cyst proliferation and to 
decrease cyst growth in male PKD animal models [11,12].  Feeding male Han:SPRD-cy rats soy 
protein slowed PKD progression by decreasing inflammation indicated by decreased renal 
cyclooxygenase-2 (COX-2) enzyme activity and renal prostanoids [12]. 
Studies have mainly been conducted in male animal models although the rate of PKD 
progression and severity is affected by gender [13].  In research conducted by Aukema and 
Housini [14] feeding soy protein reduced kidney cysts and improved renal functional 
measurements in male, but not female Han:SPRD-cy rats.  Currently, no rodent model is 
genetically orthologous while expressing phenotypes typical of human ADPKD or ARPKD.  
Therefore, Torres and Harris [15] suggested that several PKD rodent models be used to 
investigate experimental therapies.  The PCK rat, an orthologous model of human ARPKD, has a 
phenotype that resembles a slow progressing form of ARPKD [16].  To our knowledge no 
studies have examined diet therapy using the PCK rat model.  We hypothesized that the anti-
proliferative and anti-inflammatory actions associated with soy protein and n-3 PUFA 
supplementation will attenuate PKD progression in female PCK rats.  Therefore, the objective of 
this study was to investigate the role of these bioactive ingredients on PKD progression by 
randomly assigning female PCK rats to diets containing soy protein and/or n-3 PUFAs.  Due to 
the absence of human clinical trials including dietary intervention for PKD, human patients must 
relay on the evidence gained from animal models [6].  By examining various animal PKD 
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models and their reaction to various dietary components, researchers can provide PKD patients 
with a better dietary treatment plan. 
3.3.  Methods and materials 
Animals and diets 
 All animal procedures performed in this study were conducted in accordance with the 
National Research Council for the Care and Use of Laboratory Animals Guidelines [17] and 
were approved by the Animal Care and Use Committee at West Virginia University.  Young (age 
28 day) female PCK rats were purchased from Charles River Laboratories (Wilmington, MA).  
All rats were individually caged and maintained in a room kept at 21°C with a 12 hour light/dark 
cycle throughout the 12 week study period.  Following a 7 day acclimation period, animals were 
randomly assigned (n=12 rats/group) to different experimental diets.  The experimental diets 
were based on the American Institute of Nutrition-93G (AIN-93 G) diet.  The AIN-93G is a 
standard diet consisting of purified ingredients and formulated to meet all the nutritional 
requirements for growing rats as defined by the National Research Council [18].  Diet 
ingredients and fatty acid composition are provided in Table 1.  All diets were isocaloric and had 
similar ingredients except for the lipid and protein source.  The protein sources consisted of 200 
g/kg diet as casein or soy protein isolate (SPI).  Both protein sources consisted of 87% crude 
protein by proximate analysis.  SPI was generously provided by DuPont Nutrition and Health 
(St. Louis, MO).  The lipid sources consisted of 70 g/kg diet as either corn oil which is low in n-
3 PUFAs, soybean oil which contains the essential fatty acids linoleic acid (LA, 18:2n-6) and 
alpha-linolenic acid (ALA, 18:3n-3) or salmon oil which is rich in the long-chain n-3 PUFAs, 
eicosapentaenoic (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) as a 1:1 soybean oil 
+ salmon oil blend.  Salmon oil was purchased from Jedwards International Inc (Quincy, MA).  
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Our four experimental diets consisted of: 1) casein + corn oil (Casein + CO), 2) casein + soybean 
oil (Casein + SO), 3) soy protein isolate + soybean oil (SPI +SO) or 4) soy protein isolate + 1:1 
soybean/salmon oil (SPI + SB). 
To prevent variability in food intake, rats were restriction fed 15 ± 2 g of powdered diet 
daily.  This amount was based on previous studies showing young Sprague-Dawley female rats 
consuming 15 g powdered diet/d supported growth [19].  All diets were kept at -20oC until fed.  
Food intake was measured daily and replaced with fresh diet daily.  Rats were provided deonized 
distilled water (ddH2O) ad libitum.  Body weights, water consumption, and urine outputs were 
recorded weekly throughout the study.  At the end of the 12-week feeding study, rats were 
euthanized by CO2 inhalation.  Blood was collected by aorta puncture and centrifuged at 1,500 g 
for 10 min at 4 °C to obtain serum.  Right and left kidneys were excised, trimmed, decapsulated, 
and then weighed separately.  The right kidneys were flash frozen in liquid nitrogen and stored at 
−80 °C until used for fatty acid and molecular analysis.  The left kidneys were cut distally and 
the left portion was immediately fixed in a 10% formalin solution for histological evaluation. 
Histological evaluation of kidney morphometry 
The left kidneys (n=11-12) were fixed, embedded, and stained with hematoxylin and 
eosin as described in Gigliotti et al. [20].  Renal cyst number and size (0.3–1.0 mm) and 
structural abnormalities such as cyst defacement and interstitial inflammation were analyzed.  
All slides were analyzed using a Nikon TE 2000-S light microscope (Nikon Instruments, NY) at 
4X magnification by a pathologist blinded to the dietary treatments.  Images were captured using 
a PC interfaced with Q-Capture imaging software (Quantitative Imaging Corporation, BC, 
Canada). 
Analysis of serum and kidney fatty acid composition 
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Total lipids were extracted from serum and kidneys using a modified method of Bligh 
and Dyer [18].  Kidney sample were taken from a center sagittal section that included the cortex, 
medulla, and papilla.  Briefly, frozen renal tissue (~400 mg) with nonadecenoic (19:1) added as 
an internal standard was homogenized in Tris/EDTA buffer (pH 7.4).  Kidney tissue was 
homogenized in a chloroform: methanol:acetic acid (2:1:0.15 v/v/v) solution.  After 
centrifugation at 900 g for 10 min at 10°C, the bottom chloroform layer was collected.  The 
collected chloroform was filtered through 1-phase separation filters and then dried under 
nitrogen gas. 
The extracted lipid samples were transmethylated according to Fritsche and Johnston 
[22].  Dried samples were diluted in iso-octane to a concentration of 5 mg fatty acid methyl 
esters/mL iso-octane.  Samples were analyzed by gas chromatography (CP-3800, Varian, CA) as 
described in Gigliotti et al. [20].  Quantitative 37 Component fatty acid methyl esters Sigma Mix 
(Supelco, Bellefonte, PA) was used as a standard to identify fatty acids.  Fatty acids were 
determined by retention time and quantified using peak area counts.  All samples were 
performed in duplicate and reported as % total fatty acids. 
RNA isolation and gene expression analysis 
Right kidneys were frozen in liquid nitrogen and stored at -80
o
C until processed for RNA 
isolation.  Frozen tissue samples (~100 mg) were taken from a center sagittal section that include 
the cortex, medulla, and papilla.  Total renal RNA was extracted following the Total RNA 
Isolation procedure of the mirVana miRNA Isolation Kit (Ambion, TX).  Isolated RNA integrity 
was visualized on a 1.5% agarose gel and isolated RNA concentration was quantified by 
spectrophotometry (Thermo Scientific, DE).  After DNase treatment of the isolated RNA 
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(Applied Biosystems, CA), total mRNA was amplified using the Superscript III First Strand 
Synthesis assay with oligo dT primers (Invitrogen, CA). 
Primer efficiencies were determined on pooled RNA samples serially diluted in ddH2O 
up to 1:10000.  PCR consisted of 2.5µl of SYBR
®
 Green Master Mix (Applied Biosystems, CA), 
1µl of cDNA, 1µl of respective forward and reverse primers, and 0.5µl of ddH2O for a total 
reaction volume of 5µl.  The thermal profile consisted of 50°C for 2 minutes, 95°C for 10 
minutes, and then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.  Primers were 
designed for rat cyclooxygenase -2 (COX-2), mammalian target of rapamycin (mTOR), mitogen-
activated protein kinase (MapK), and peroxisome proliferator-activated receptor gamma 
(PPARγ) and the housekeeping gene beta actin using the Primer3 program (Howard Hughes 
Medical Institute) and respective mRNA sequences obtained from NCBI.  Forward and reverse 
primers for genes were: COX-2 (PTGS2) 5’ CGGAGGAGAAGTGGGTTTTAG 3’, and 5’ 
TGAAAGAGGCAAAGGGACAC 3’; mTOR 5’ GGCTTCAACAGCAAGGACAC 3’ and 5’ 
ACGGGTGAGGTAACAGGATG 3’; MapK 5’CGTTCAGATGTCGGTGTCC 3’ and 
5’CGGCTCAAAGGAGTCAAGAG 3’; PPARγ 5’ TGGAGCCTAAGTTTGAGTTTGC 3’ and 
5’CAGCAGGTTGTCTTGGATGTC 3’.  All primers were normalized to beta actin 5’ 
TTGCTGACAGGATGCAGAAG 3’ and 5’ CAGTGAGGCCAGGATAGAGC 3’.  
Biomarkers of kidney function 
Serum measures of renal function were determined enzymatically using a commercially 
available Vet-16 rotor and quantified by a Hemagen Analyst automated spectrophotometer 
(Hemagen Diagnostics Inc., Columbia, MD).  
Statistical analyses 
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A power analysis conducted prior to the experiment showed that with a minimum of 10 
rats/group at an alpha=0.05 there is 80% power to detect a difference in renal weight among the 
dietary treatment groups.  Results are expressed as means ± standard error of the mean (SEM).  
One-way analysis of variance (ANOVA) was used to determine differences among treatment 
groups.  Post-hoc multiple comparisons were performed using Tukey's test.  Differences were 
considered significant at P<0.05.  All statistical analyses were performed using SigmaStat 3.1 
statistical software program (Systat Software Inc., San Jose, CA).  Relative gene expression was 
calculated according to methods by Bari et al [23], with values obtained by calculating 40-DCt.  
DCt was calculated as the difference in threshold cycle (Ct) of the gene of interest and the 
reference gene (ActB) while the number 40 was selected because it represents the highest Ct 
value.  Following the 40-DCt calculation, gene expression was analyzed using a one way 
ANOVA. 
3.4  Results 
Body weight and kidney mass 
There were no significant differences in food intake for rats fed Casein+CO (15.0+0.4 g), 
Casein+SO (15.0+0.4 g), SPI+SO (15.1+ 0.4 g) or SPI+SB diet (15.3+1.4 g).  There were no 
significant differences in initial body weight, body weight gain, and final body weight among 
rats fed the different diets (Table 2).  There were no significant differences in water consumption 
among rats fed the different diets.  There were also no significant differences in relative kidney 
weights among growing female PCK rats fed the different diets (Table 2).  A student’s t-test 
determined there were no differences (P< 0.67) between right and left kidney weights in any of 
the dietary treatments. 
Kidney histology 
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At the end of the 12-week study, all female PCK rats had the same sizes of cortical and 
medullary cysts regardless of diet.  Figure 1 is representative H&E staining of renal cysts (1a), 
inflammation (1b), and fibrosis (1c).  All rats also had interstitial inflammation, fibrotic changes, 
interstitial matrix deposition, and structural effacement due to cyst growth indicating disease 
progression (Table 3).  Cortical cyst obstruction was observed in rats fed SPI + SB diet.  There 
were no significant differences in any other histological measurements between rats fed the 
different diets. 
Renal tissue fatty acid composition  
There were no significant differences in tissue renal linoleic acid (LA, 18:2n-6) content 
among the diet treatment groups.  Renal arachidonic acid (AA, 20:4n-6) content was 
significantly lower in rats fed the SPI +SO and SPI + SB diet compared to rats fed Casein + CO 
and Casein + SO diet (Table 4). 
Total n-3 PUFA intake was highest (P<0.001) in rats fed SPI+SB diet (2.49+0.06 g).  
Rats fed Casein+SO (1.17+0.03 g) and SPI+SO (1.18+0.03 g) had significantly higher total n-3 
PUFA intake than rats fed Casein+CO (0.89+0.02 g) diet.  Final serum ALA was highest 
(P=0.01) in rats fed diets with SO as the oil source.  Serum EPA and DHA was highest in rats 
fed the SPI+SB diet.  Rats diets with SO had significantly higher serum EPA and DHA than rats 
fed Casein+CO.  Serum AA was reduced (P=0.04) in rats fed SPI+SB compared to Casein+CO 
diet. 
Rats fed either Casein or SPI with SO as the lipid source had higher (P< 0.001) renal 
tissue ALA content than rats fed SPI + SB diet.  Rats fed Casein+ CO diet had the lowest (P< 
0.001) renal ALA content.  There were no differences in renal tissue EPA content among the diet 
treatment groups.  Rats fed SPI + SB diet had the highest (P< 0.001) renal DHA content.  Rats 
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fed SO as the lipid source as Casein or SPI diet had similar renal DHA content.  Rats fed Casein 
+ CO diet had the lowest (P< 0.001) renal DHA content (Table 4). 
Renal gene expression analysis 
There were no significant differences in renal relative gene expression of PPARγ, COX2, 
MapK, and mTOR between rats fed the different diets (Figure 2A-D). 
Biomarkers of kidney function 
Rats fed the SPI +SB diet had the highest (P = 0.01) serum BUN concentration.  Rats fed 
Casein + SO diet had the lowest (P = 0.01) serum BUN concentration.  There were no significant 
differences in renal function measurements of serum uric acid, total protein, globulin, albumin, 
albumin/globulin, calcium or phosphorus among the diet treatment groups (Table 5). 
 
3.5.  Discussion 
Multiple cyst formation in PKD increases renal size [24].  In our study, growing female 
PCK rats fed different lipid sources for 12 weeks resulted in no significant differences in relative 
kidney weights.  Similarly, growing male and female Han:SPRD-cy rats fed 7% wt corn oil or 
ALA rich flaxseed oil for 12 weeks resulted in no significant differences in relative kidney 
weights [9].  However, female DBA/2FG-pcy mice, a rodent model of adolescent 
nephronophthisis, fed EPA-enriched diets for 60 days significantly reduced mean kidney weights 
compared female mice fed n-6 PUFA rich sunflower seed oil [25].  This may be due to species 
and disease model differences among the studies. 
In our study, growing female PCK rats fed different protein sources also produced no 
significant differences in relative kidney weights.  However, growing female and male 
Han:SPRD-cy rats fed 20% wt soy protein had  significantly decreased kidney weights compared 
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to casein-fed rats [14].  The inconsistent findings can be attributed to differences in the disease 
model used.  It is important to evaluate dietary treatments using several models due to the 
absence of PKD rodent models that are orthologous to human PKD. The PCK rat model displays 
the Pkhd1 gene mutation orthologous to human ARPKD [5,16] thus, making it an attractive 
model to examine the effectiveness of dietary treatment in ARPKD. 
Multiple cyst formation in PKD enlarges renal size, which increases the risk of structural 
damage and loss of renal function [24].  At the end of our 12 week study, all growing female 
PCK rats showed histological evidence of renal cysts.  There were no significant differences on 
the number or size of cortical or medullary cysts among the diet treatment groups.  The results 
indicated that soy protein and/or n-3 PUFAs did not slow disease progression.  Similarly, female 
and male DBA/2FG-pcy mice (age 50-58 d) fed n-3 PUFA as EPA-enriched fish oil concentrate 
for 60 days had similar renal cyst area compared to mice fed sunflower seed oil low in n-3 
PUFAs [26].  However, growing male Han:SPRD-cy rats fed 20% wt soy protein reduced renal 
cyst size compared male rats fed casein for 8 and 12 weeks [14,27].  Dietary intervention may 
differed in the PCK female rat model, a model of ARPKD compared to the Han:SPRD-cy rat 
model, a model of ADPKD.  Renal pathology in PCK rats is characterized by damage to the 
collecting ducts and distal nephron while in the Han:SPRD-cy rat renal pathology is 
characterized by damage to proximal tubules and all sections of the nephron [15,28].  Also, 
earlier dietary intervention may be required in ARPKD since disease onset occurs in utero or 
shortly after birth.  Cahill et al. [29] exposed male Han:SPRD-cy rats offspring to soy protein 
prenatally and during lactation.  Offspring exposed to soy protein in utero and during pregnancy 
had reduced renal cyst changes as well as improved renal function.  The observation of greater 
beneficial effects when soy protein was provided in utero and during lactation has important 
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implication for ADPKD, but may be of particular significance to ARPKD with infantile disease 
onset. 
In some animal studies, soy protein intake attenuated the early stages of cyst pathogenesis 
indicated by reduced epithelial cell proliferation [6].  MapK and mTOR are key transcription 
factors regulating cell proliferation [30].  In our study, MapK and mTOR gene expression were 
not significantly down-regulated in female PCK rats fed soy protein at weaning compared to 
casein fed rats.  Cyst pathogenesis is characterized by initial proliferation of tubular epithelial 
cells followed by inflammation and fibrosis as the disease progresses [31].  In our study, cortical 
cyst obstruction was observed in rats fed SPI + SB diet.  Histological evaluation of the kidneys 
of rats fed SPI+SB diet showed no significant difference in inflammation or fibrosis compared to 
the other dietary treatment groups.  Cyst obstruction may not have resulted in sufficient damage 
at 12 weeks to promote significantly greater inflammation or fibrosis. 
Rats fed SPI + SB diet also resulted in the highest (P=0.01) serum BUN concentrations.   
Detrimental effects were unexpected since higher tissue EPA or DHA content replaces tissue n-6 
PUFA, AA content.  AA can be converted by the enzyme COX-2 to eicosanoids with pro-
inflammatory properties, therefore decreasing tissue AA content may reduce inflammation [32]. 
Rats fed SPI+SB diet had the highest (P=0.03) serum EPA and DHA and reduced (P=0.04) 
ARA.  In renal tissue rat fed SPI+SB diet also had the highest (P< 0.001) renal DHA content and 
reduced ARA (P< 0.001), but there was no significant differences in renal EPA content 
compared to the other diet treatment groups.  EPA may have be used for eicosanoid production 
due to renal damage resulting from greater cyst obstruction in rat fed SPI+SB diet.  Altered 
phospholipase A2 and COX activity in disease kidneys has been reported for pcy mouse and 
Hans:SPRD-cy rats [33].  Rats fed SPI with lipid sources as soybean oil also had lower (P< 
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0.001) renal AA content than rats fed Casein + SO.  Ogborn et al. [9] suggested that soy protein 
inhibits Δ6 desaturase enzyme, which plays a role in the conversion of the essential n-6 PUFA, 
LA (18:2n-6) to the long-chain n-6 PUFA, AA (20:4n-6). 
Female PCK rats fed SPI+SB diet had the highest renal tissue DHA content and reduced 
tissue AA content resulted in higher cyst obstruction and reduced renal function.  While dietary 
fish oil rich in DHA had protective effects in Han:SPRD-cy rats, Sankaran et al. [34] reported 
exacerbation of PKD progression in weanling pcy rats fed DHA-rich algal oil.  The authors 
suggested this was due to increased renal long-chain n-3 PUFA content at the expense of n-6 
PUFAs resulting in inadequate n-6 PUFA content in tissue, eicosanoid imbalance, and higher 
risk of tissue oxidation. 
In our study there were no significant differences in COX-2 gene expression among any 
of the diet treatment groups.  In contrast, Sankaran et al. [35] reported weanling CD1-pcy/pcy 
mice and Han:SPRD-cy rats fed 7% and 20% (wt) menhaden oil rich in EPA and DHA or DHA-
rich algae oil, but not ALA rich flaxseed oil up-regulated COX-2 kidney gene expression levels 
compared to rats fed CO [34,35].  These studies used a higher n-3 PUFA doses of up to 20% wt 
as pure fish oil or algae oil which likely resulted in higher EPA and DHA content compared to a 
1:1 salmon oil and soybean oil blend.  The n-3 PUFAs may also influence inflammation by other 
pathways than COX such as altering transcription factors regulating inflammation gene 
expression [36].  PPARγ is part of the ligand-dependent nuclear receptor family expressed in the 
kidneys where it plays a role in cellular proliferation, fibrosis, and inflammation that can be 
activated by fatty acids [37].  Yoshihara et al. [38] reported male and female PCK rats treated 
with PPARγ agonist decreased kidney weight and cysts.  In our study, there were no significant 
differences in PPARγ expression, kidney weights and cysts among PCK rats fed different dietary 
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treatments for 12 weeks.  In the Yoshihara et al. [38] study rats were provided PPARγ agonist 
drugs for 16 weeks. 
The advantage of using a dietary approach is that a simple modification such as water 
intake has the potential to improve renal health in PKD patients.  Nagao et al. [39] reported 
slowed renal cyst growth in PCK rats that increased fluid intake sufficient to lower urine 
osmolality in comparison to animals who drank water ad libitum.  In a pilot study of female 
ADPKD patients (n=8) water prescription of 3-4 L reduced urine osmolality, however renal 
cytogenesis was not assessed [40].  In our animal study there were no significant differences in 
water intake; therefore, any effects on PKD progression and severity were attributable to the 
different dietary lipids and/or proteins. 
Sarwar and others [41] found that different protein quality influenced rat growth.  Since a 
common strategy in diet management of renal disease is to maintain a healthy body weight [42], 
it is important to determine whether different protein and lipid sources support adequate growth.  
In the present study, growing female PCK rats fed 20% wt (87% purity) protein as either soy 
protein or casein and 7% wt lipid from corn oil low in n-3 PUFAs, soybean oil moderate in n-3 
PUFAs or a soybean oil:salmon oil blend rich in n-3 PUFAs for 12 weeks showed no significant 
differences in weight gain or final body weights.  The results indicated that all experimental diets 
were similar for supporting body growth.  Similarly, Aukema and Housini [14] reported that 
growing female Han:SPRD-cy rats, a non-orthologous rodent model of ADPKD, fed 20% wt soy 
protein for 6 weeks had similar body weights to rats fed 20% wt casein.  Ogborn et al. [42] 
reported that growing female Han:SPRD-cy rats fed 7% wt corn oil low in n-3 PUFAs for 12 
weeks had similar body weights and growth compared to rats fed flaxseed oil rich in n-3 PUFAs. 
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Some study limitations are diet restriction supported growth, but the possibility that 
higher intakes due to ad libitum consumption can influence PKD progression cannot be 
discounted.  Cysts were detectable in all groups at 12 weeks, but detectable dietary effects may 
require a longer feeding since PKD disease progresses more slowly in female than male and the 
PCK rat model is a slow progressing form of ARPKD [15-16].  The hypothesis that soy protein 
and n-3 fatty acids will attenuate disease progression was rejected based on the results showing 
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Table 1.  Ingredient composition of the diets fed to rats. 
Ingredient (g/kg diet)
1 
Casein + CO Casein + SO SPI + SO SPI + SB 
Casein 200.0 200.0 0.0 0.0 
Soy protein isolate 0.0 0.0 200.0 200.0 
L-Cystine 3.0 3.0 1.3 1.3 
Corn Starch 397.5 397.5 397.5 397.5 
Maltodextrin 132.0 132.0 132.0 132.0 
Sucrose 100.0 100.0 100.0 100.0 
Soybean Oil 70.0 0.0 70.0 35.0 
Corn Oil 0.0 70.0 0.0 0.0 
Salmon Oil 0.0 0.0 0.0 35.0 
Cellulose 50.0 50.0 50.0 50.0 
Mineral Mix
2 
35.0 35.0 35.0 35.0 
Vitamin Mix
2 
10.0 10.0 10.0 10.0 
Choline bitartrate 2.5 2.5 2.5 2.5 
TBHQ, antioxidant 0.014 0.014 0.014 0.014 
Calories 377 377 377 377 
     
Fatty acids (%)     
n-3 PUFAs     
Alpha-linolenic acid (ALA, 18:3n-3) 0.59+0.18c 7.69+0.02a 7.68+0.04a 4.85+0.01b 
Eicosapentaenoic acid (EPA, 20:5n-3) ND ND ND 7.4+0.03 
Docosahexaenoic acid (DHA, 22:6n-3) ND ND ND 3.9+0.1 
n-6 PUFAs     
Linoleic acid (LA, 18:2n-6) 52.93+2.68a 55.78+0.07a 56.09+0.09a 35.19+0.06b 
Arachidonic acid (ARA, 20:4n-6) 1.10+0.04a 0.16+0.005c 0.21+0.01c 0.41+0.007b 
1
All ingredients are from Harlan Teklad except for SPI from DuPont Nutrition and Health (St. 
Louis, MO) and salmon oil from Jedwards International (Quincy, MA). 
2
Based on the AIN-93G vitamin and mineral mixes.  Different superscript letters a, b, c within 
the same rows indicate significant differences at P<0.05 by one-way ANOVA followed by 
Tukey’s test.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy protein isolate; SB, 1:1 
soybean oil:salmon oil blend; TBHQ, tertiary butylhydroquinone; ND, not detectable.
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Table 2.  Body weight, body gain, water intake, and kidney weights in female PCK rats fed various protein and lipid sources. 
 
Values are the mean ± SEM of n=11-12 rats/group.  Different means were compared by one-way ANOVA with significant differences 
at a P value of <0.05.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy protein isolate; SB, 1:1 soybean oil:salmon oil blend.
Measurements Casein + CO Casein + SO SPI + SO SPI + SB P-value 
Initial body weight (g) 87 ± 6  86 ± 6  95 ± 6  93 ± 7  0.66 
Body weight gain (g) 184 ± 6 184 ± 5 176 ± 5 186 ± 13 0.78 
Final body weight (g) 271 ± 2 270 ± 3 281 ± 9 269 ± 4 0.32 
Water intake (mL) 14.4 ± 9.4 15.2 ± 13.7 16.3 ± 11.5 16.5 ± 12.3 0.79 
Relative left kidney weight 
(g/100 g kidneys) 
4.4 ± 0.1 4.3 ± 0.1 4.6 ±0.2 4.8 ± 0.2 0.09 
Relative right kidney weight 
(g/100 g kidney) 
4.3 ± 0.1 4.3 ± 0.1 4.5 ± 0.1 4.6 ± 0.2 0.21 
Relative total kidney weights (g) 
(g/100 g kidney) 
8.6 ± 0.2 8.5 ± 0.2 9.1 ± 0.3 9.3 ± 0.4 0.12 
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alues are the mean ± SEM of n=11-12 rats/group.  Different means were compared by one-way ANOVA with significant 
differences at a P value of <0.05.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy protein isolate; SB, 1:1 soybean 
oil:salmon oil blend.
Measurements Casein + CO Casein + SO SPI + SO SPI + SB P-value 
Number of medullary cysts ≥ 1.0 mm 6.7 ± 1.1 5.8 ± 1.5 5.2 ± 1.3 6.3 ± 1.0 0.84 
Number of cortical cysts ≥ 0.3 mm 2.6 ± 0.7 2.4 ± 0.7 2.3 ± 1.0 1.8 ± 0.5 0.91 
Structural effacement by cysts 2.7 ± 0.2 2.3 ± 0.3 2.4 ± 0.3 2.6 ± 0.2 0.55 
Cortical cystic change Present Present Present Present  
Cortical cyst obstruction Not Present Not Present Not Present Present  
Medullary cystic change Present Present Present Present  
Interstitial inflammation 1.6 ± 0.1 1.5 ± 0.2 1.5 ± 0.2 1.4 ± 0.2 0.89 
Tubulo-interstitial fibrotic changes 1.3 ± 0.2 1.0 ± 0.2 1.0 ± 0.2 1.2 ± 0.1 0.49 
Tubulo-interstitial matrix 
deposition 
0.9 ± 0.3 0.3 ± 0.1 1.0 ± 0.2 1.1 ± 0.3 0.08 
Glomerular hypercellularity Not Present Not Present Not Present Not Present  
Glomerular matrix deposition Not Present Not Present Not Present Not Present  
Arteriolosclerosis Not Present Not Present Not Present Not Present  
Interstitial calcification Not Present Not Present Not Present Not Present  
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Values are the mean ± SEM of n=11-12 rats/group.  Different superscript letters a, b, c within the same rows indicate significant 
differences at P<0.05 by one-way ANOVA followed by Tukey’s test.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy 
protein isolate; SB, 1:1 soybean oil:salmon oil blend; n-6 PUFAs, omega-6 polyunsaturated fatty acids; n-3 PUFAs, omega-3 
polyunsaturated fatty acids.
Measurements 
(% total fatty acids) 
Casein + CO Casein + SO SPI + SO SPI + SB P-value 
Kidney      
n-6 PUFAs
      
Linoleic acid (18:2) 7.95 ± 0.39  9.81 ± 0.61  10.05 ± 0.84  11.06 ± 0.94  0.05 
Arachadonic acid (20:4) 17.83 ± 0.59 a 15.83 ± 0.37 a 12.97 ± 1.35 b 10.49 ± 0.82 b <0.001 
n-3 PUFAs
      
Alpha-linolenic acid (18:3) 0.09 ± 0.004 c 0.46 ± 0.04 a 0.41 ± 0.05 a  0.30 ± 0.02 b <0.001 
Eicosapentaenoic acid (20:5) 1.73 ± 0.12 2.06 ± 0.09 2.14 ± 0.25 2.33 ± 0.31 0.33 
Docosahexaenoic acid (22:6) 0.89 ± 0.18 c 1.99 ± 0.04 b 1.93 ± 0.22 b 4.25 ± 0.17 a <0.001 
Final Serum      
Linoleic acid (18:2) 24.27 ± 2.48a 12.56 ± 0.69b  11.02 ± 0.70b  7.61 ± 0.25b <0.05 
Arachadonic acid (20:4) 0.43 ± 0.07a 0.39 ± 0.07ab 0.42 ± 0.13ab      0.14 ± 0.02b 0.04 
n-3 PUFAs
      
Alpha-linolenic acid (18:3) 0.21 ± 0.07 b 0.67 ± 0.05 a 0.76 ± 0.3 a  0.35 ± 0.01 b <0.001 
Eicosapentaenoic acid (20:5) 0.47 ± 0.04 0.66 ± 0.01 0.76 ± 0.05 1.41 ± 0.12 0.33 
Docosahexaenoic acid (22:6) 0 c 1.00 ± 0.31b 1.29 ± 0.08 b 4.13 ± 0.53 a <0.001 
55 
Table 5. Serum measurements in female PCK rats fed various protein and lipid sources. 
 
Values are the mean ± SEM of n=11-12 rats/group.  Different superscript letters a, b, c within the same rows indicate significant 
differences at P<0.05 by one-way ANOVA followed by Tukey’s test.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy 
protein isolate; SB, 1:1 soybean oil:salmon oil blend.
Measurements Casein + CO Casein + SO SPI + SO SPI + SB P-value 
Serum Blood Urea Nitrogen 
(mg/dL) 
10.1 ± 0.5 b 9.3 ± 0.8 c  11.6 ± 0.5 b 11.8 ± 0.6 a 0.01 
Serum Uric Acid (mg/dL) 4.8 ± 0.3 5.3 ± 0.5 5.1± 0.4 4.7 ± 0.2 0.65 
Serum Total protein (g/dL) 6.2 ± 0.4 6.4 ± 0.3 6.5 ± 0.4 6.4 ± 0.3 0.92 
Serum Globulin (g/dL) 2.4 ± 0.2 2.6 ± 0.2 3.0 ± 0.5 2.9 ± 0.3 0.66 
Serum Albumin (g/dL) 3.8 ± 0.1 3.8 ± 0.1 3.6 ± 0.2 3.5 ± 0.2 0.55 
Serum Albumin/Globulin 
(g/dL) 
2.1 ± 0.5 1.5 ± 0.1 1.5 ± 0.2 1.5 ± 0.2 0.44 
Serum Calcium (mg/dL) 11.7 ± 0.4 11.7 ± 0.1 11.0 ± 0.4 11.0 ± 0.3 0.17 
Serum Phosphorus (mg/dL) 12.1 ± 0.6 13.1 ± 0.7 11.5 + 0.6 12.0 ± 0.5 0.32 
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Figure 1 A-C.  Histological evaluation by H&E staining of kidneys from female PCK rats fed 














Figure 2 A-D.  Renal genetic expression levels of (A) PPAR-gamma, (B) COX-2, (C) MAPK, 
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4.1.  Abstract 
 
Polycystic kidney disease (PKD), a genetic disorder characterized by multiple cysts, 
leads to loss of kidney function and renal failure at an early age.  Optimizing bone health during 
the growth stage may protect against bone loss associated with early renal dysfunction in PKD.  
Soy protein and omega-3 polyunsaturated fatty acids (n-3 PUFAs) are nutrients reported to 
ameliorate PKD, to prevent bone loss in ovarectomized rats, and to enhance bone in non-
diseased animals.  The study objective was to determine the effects of feeding soy protein and/or 
n-3 PUFAs in PCK rats, a model of PKD on bone.  Weanling female PCK rats (n=12/group) 
were randomly assigned to casein + corn oil (Casein + CO), casein + soybean oil (Casein + SO), 
soy protein isolate + soybean oil (SPI + SO) or soy protein isolate + 1:1 soybean oil:salmon oil 
blend (SPI + SB).  At 12 weeks, rats fed the SPI+SO diet had lower (P=0.001) femur length than 
casein-fed rats.  Rats fed SPI+SB diet had higher (P=0.01) calcium (Ca) and phosphorus (P) 
retention.  However, there were no significant differences between diet groups in Ca, P or bone 
mass.  There were also no significant difference in bone microarchitecture according to micro-
computed tomography or bone strength by three-point bending test between diet groups.  Early 
diet management using SPI and/or n-3 PUFAs neither worsens nor enhances bone 
mineralization, microarchitecture or strength, but influenced other renal disease complications of 
longitudinal bone growth and mineral metabolism indicated by effects on femur length and by 
increased mineral retention. 
 
 
Keywords: omega-3 fatty acids, protein, mineral balance, long bones, polycystic kidney disease 
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4.2.  Introduction 
In children, kidney diseases are often accompanied by disordered mineral metabolism, 
decrease in maximum adult height achieved, and failure to achieve peak bone mass (PBM) [1-2].  
Furthermore, epidemiological studies demonstrated greater incidence of bone fractures in end 
stage renal disease (ESRD) patients [3].  Worldwide, the third most common cause of ESRD is 
polycystic kidney disease (PKD) characterized by multiple cysts that lead to massive 
enlargement of the kidneys and loss of renal function [4].  In autosomal dominant polycystic 
kidney disease (ADPKD), the most prevalent inherited form of PKD, individuals are 
asymptomatic until the third or fifth decades of life [5].  In the rarer autosomal recessive 
polycystic kidney disease (ARPKD), disease onset occurs early in childhood with more than 
50% of affected children progressing to ESRD in the first decade of life [6].  Common strategies 
for the management of renal disease and the resulting sketetal phenotype in childhood are to 
promote a healthy body weight and to maximize PBM. 
Soy protein and omega-3 polyunsaturated fatty acids (n-3 PUFAs) are dietary 
components found in pre-clinical studies to ameliorate PKD progression and severity [7], to 
improve bone health, and to attenuate bone loss leading to osteoporosis [8-10].  Dietary protein 
restriction is advocated as a dietary regimen to attenuate renal disease and to delay the onset of 
ESRD, although evidence for its clinical effectiveness and feasibility is controversial [11].  
Therefore, efforts to discern the best dietary approach as it relates to protein have focused on 
investigating the protein source rather than the amount consumed [12].  Feeding growing 
Hans:SPRD-cy rats, an animal model of ADPKD, soy protein isolate (SPI) has been shown to 
slow PKD progression and severity compared to rats fed the milk protein, casein [12-13].  
Hans:SPRD-cy rats were derived from spontaneous mutations in Sprague-Dawley rats [14].  
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Feeding growing female Sprague-Dawley rats SPI enhanced bone mineral content (BMC) and 
bone mineral density (BMD) compared to casein [15].  The commercially available PCK rat 
derived from a Sprague-Dawley outbred strain is genetically orthologous to human ARPKD 
[14].  The PCK rat has been used for preclinical testing of treatment options for PKD [16].  To 
our knowledge no studies have investigated the effects of dietary SPI on PCK rats. 
Previously, we reported that female Sprague-Dawley rats (age 28 d) fed fish oil rich in 
the long-chain n-3 PUFAs, eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaeonic acid 
(DHA, 22:6 n-3) increased femur and tibial BMD and BMC; whereas, flaxseed oil rich in the n-3 
PUFA, alpha linolenic acid (ALA, 18:3n-3) improved long bone trabecular microarchitecture 
compared to rats fed corn oil [17].  Female Han:SPRD-cy rats (age 21 d) fed ALA-rich flaxseed 
oil had higher whole body BMC and BMD compared to animals fed corn oil low in n-3 PUFAs 
[18].  These studies demonstrated favorable effects of n-3 PUFA intake on bone in young 
growing non-diseased and ADPKD rats.  To our knowledge no studies have investigated whether 
dietary n-3 PUFAs can enhance bone health in PCK rats. 
There has been a lack of research regarding the potential bone effects of PKD, 
particularly in ARPKD, because the priority in PKD therapy strategies has been to slow 
progression to hypertension, renal failure, and early age at morbidity.  Studies are needed 
because many drugs used in the treatment of osteoporosis are not approved for use in patients 
with moderate to advanced kidney diseases [3].  Also, drug therapies in development to treat 
PKD such as peroxisome-proliferator-activated receptor-gamma agonists have reported side 
effects that include bone loss [19].  Early diet management by optimizing bone health during the 
growth stage can potentially minimize bone loss due to renal dysfunction and ERSD at an early 
age in PKD patients [5-6].  Therefore, the objective of this study was to determine the whether 
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feeding growing female PCK rats SPI and/or n-3 PUFAs can enhance bone morphometry, 
mineralization, microarchitecture, and strength. 
4.3.  Materials and Methods 
Animals and Diets 
All animal procedures were conducted in accordance with the Institute of Laboratory 
Animal for the Care and Use of Laboratory Animals Guidelines [20], and were approved by the 
Animal Care and Use Committee at West Virginia University.  Growing (age 28 d) female PCK 
rats were purchased from Charles River Laboratories (Wilmington, MA).  All rats were kept in a 
21°C room with a 12 hour light/dark cycle throughout the 12 week study period.  Following a 7 
day acclimation period, animals were randomly assigned (n=12 rats/group) to experimental diets.  
A power analysis was conducted prior to the experiment showed that with 10 rats/group at an 
alpha=0.05 there is 80% power to detect a difference in BMD and microarchitecture between the 
diet groups.  An additional 1-2% rats was included due to possibility of morbidity or mortality 
due to disease in PCK rats. 
The experimental diets were based on the American Institute of Nutrition-93G (AIN-93 
G) diet.  The AIN-93G is a standard diet consisting of purified ingredients and formulated to 
meet all the nutritional requirements for growing rats as defined by the National Research 
Council [21].  The AIN-93G diet is formulated with casein as the protein source (200 g/kg diet) 
and soybean oil (SO) as the lipid source (70 g/kg diet).  SO contains both essential fatty acids, 
the n-6 PUFA, linoleic acid (LA, 18:2n-6) and the n-3 PUFA, ALA.  The experimental diets 
consisted of casein or SPI as the protein source.  SPI was generously provided by DuPont 
Nutrition and Health (St. Louis, MO).  The lipid sources in the experimental diets consisted of 
CO because it is high in n-6 PUFA and low in n-3 PUFAs which is typical of Western diets [22], 
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soybean oil or a 1:1 ratio of soybean oil:salmon oil to provide a source of the n-3 PUFA, ALA as 
well as long-chain n-3 PUFAs, DHA and particularly EPA.  Salmon oil was purchased from 
JEdwards International Inc (Quincy, MA).  The experimental diets consisted of: 1) casein + corn 
oil (Casein + CO), 2) casein + soybean oil (Casein + SO), 3) soy protein isolate + soybean oil 
(SPI +SO) or 4) soy protein isolate + 1:1 soybean/salmon oil (SPI + SB).  All experimental diets 
were manufactured by Harlan Teklad (Madison, WI).  Ingredients and fatty acid analysis are 
provided in Table 1. 
To prevent variation in total caloric and nutrient intake, all diets were adjusted to be 
isocaloric and rats were provided 15 ± 2 g of powdered diet daily.  This is based on previous 
studies showing growing female rats consume 15 g powdered diet/d [23].  All diets were kept at 
-20
o
C until fed.  Fresh diet was provided daily.  Rats were provided deonized distilled water 
(ddH2O) to prevent mineral intake from sources other than the diet.  Body weights were 
measured weekly throughout the 12 weeks study. 
Mineral Balance 
Rats were individually housed in metabolic cages during the final week of the 12 weeks 
feeding study to collect urine and feces.  Final 7 d urine samples were collected and centrifuged 
at 1,500 g for 10 min at 4 °C, filtered through Whatman no. 1 paper, and diluted 1:10 in ddH2O.  
Urinary calcium (Ca) and phosphorus (P) concentrations were determined using inductively 
coupled plasma spectrometry (ICP, model P400, Perkin Elmer, Shelton, CN).  Urinary values 
were corrected for urinary creatinine.  Creatinine was measured using a colorimetric assay kit 
(Cayman Chemical, Ann Arbor, MI) and absorbance read at 500 nm using a Spectramax Plus 
microplate reader (Molecular Devices, Sunnyvale, CA).  Urinary creatinine values were higher 
(P<0.05) for rats fed the Casein+CO diet (58.6+9.6 mg/dl) and Casein+SO (40.2+5.4 mg/dl) 
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compared to rats fed the SPI+SO diet (20.7+3.4 mg/dl) and SPI+SB diet (26.9+5.4 mg/dl).  All 
urinary measurements were adjusted for creatinine. 
Diet and fecal samples were freeze-dried for 48 h, ashed in a muffle furnace at 550°C for 
24 h, and then acidified in 70% nitric acid.  The acidified samples were neutralized in ddH2O, 
filtered through Whatman no. 1 paper, diluted 1:50 in ddH2O, and fecal Ca and P content 
determined by ICP. 
Bone Morphometry 
Following euthanization by CO2 asphyxiation, the right and left femurs and tibiae were 
collected (n=12 rats/group).  Bones were defleshed and morphometry measurements of medial 
lateral width, anterior posterior width, and length were determined using a vernier caliper (Bel-Art 
Products, Pequannock, NJ).  Length was measured from the medial condyle to greater trochanter.  
Bones were dried at 110
o
C for 48 h then weighed using an analytical balance (Mettler Toledo, 
Columbus, OH).  Morphometry measurements were averaged for bone pairs (i.e. right and left) after 
no bilateral differences were determined using paired t-test with significance level set at P<0.05. 
Bone Turnover Markers 
Serum samples were stored at -80
o
C until assayed.  Serum osteocalcin, a marker of 
osteoblast activity was determined using a commercially available rat specific osteocalcin 
enzyme immunoassay (EIA) (Biomedical Technologies, Stoughton, MA).  Urinary 
deoxypyridinoline (DPD) crosslinks, a marker of osteoclast activity, was determined by 
commercially available EIA kit (Quidel Corporation, CA).  Serum osteocalcin was measured at 
450 nm and urinary DPD was read at 405 nm using a Spectramax Plus microplate reader 
(Molecular Devices, Sunnyvale, CA). 
Bone Densitometry, Ash, Ca, and P 
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Dual energy X-ray absorptiometry (DXA) scans (Hologic QDR 4500-A Elite) were 
performed on the left bones.  Tibial and femoral specimens were placed in Millipore water.  
Bone mineral area (BMA), BMC, BMD were evaluated from all scans using the Regional High 
Resolution software package designed for studying isolated bone specimens (Hologic Waltham, 
MA). 
Following DXA, bones were ashed in a muffle furnace (model CP18210, Thermolyne, 
Dubuque, IA) at 600
o
C for 24 h then weighed.  Bone ash was dissolved in 2 mL of 70% nitric acid.  
Acidified samples were filtered through Whatman no. 1 paper and diluted (1:500 v/v) to volume 
with ddH2O.  Bone Ca and P content of the samples were measured using inductively coupled 
plasma optical emission spectrometry (model P400, Perkin Elmer, Shelton, CT). 
Trabecular and Cortical Bone Microarchitectural Analyses 
Trabecular and cortical bone architecture was determined in the left bones using micro-
computed tomography (μCT) (MicroCT40, SCANCO Medical, Switzerland).  Cortical bone 
architecture was evaluated on a 512 μm region of the femur and tibia mid-diaphysis.  Cortical 
indices included the medullary area and cortical thickness, area, and porosity.  The trabecular 
bone within the distal femur metaphysis and proximal tibial metaphysis were scanned and 200 
images (~16 μm/slice or 3.2 mm) were analyzed with semi-automatically drawn contours 
beginning 400 μm from the growth plate including only secondary spongiosa within the volume 
of interest.  The volume of interest was assessed for structural parameters included trabecular 
bone volume per unit of total volume (BV/TV), trabecular number (TbN), trabecular thickness 
(TbTH), trabecular connectivity, trabecular separation (TbSp), and structure model index (SMI).  
All scans were performed utilizing a 1024 x 1024 matrix resulting in an isotropic voxel 
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resolution of 22 μm3.  An integration time of 70 milliseconds per projection was used with a 
rotational step of 0.36
o
 resulting in total acquisition time of approximately 150 min/sample. 
Bone Biomechanical Strength 
Bone strength indices were assessed using a TA.XT2i Texture Analyzer (Texture 
Technologies, Scarsdale, NY) outfitted with a three-point bending apparatus.  Femora and tibiae 
were placed on supports and force applied on the medial surface of the bones by lowering a 
centrally placed blade (1 mm width) at a constant crosshead speed (0.1 mm/sec) until the bone 
was broken.  The load cell was 250 kg.  The load-deflection data were collected by a PC 
interfaced with the TA.XT2i.  Sample test distance was set at 10 mm with a signal collection rate 
of 100 points per sec. 
Statistical Analysis 
Results are expressed as means ± standard error of the mean (SEM).  One way analysis of 
variance (ANOVA) was used to determine differences between treatment groups.  Post-hoc 
multiple comparisons were performed using Tukey's test (parametric) or Wilcoxon rank test 
(non-parametric).  Differences were considered significant at P<0.05.  All statistical analyses 
were performed using SigmaStat 3.1 statistical software program (Systat Software Inc., San Jose, 
CA). 
4.4.  Results and Discussion 
Growing female PCK rats fed different protein sources as casein or SPI for 12 weeks had 
similar body weights (Figure 1).  Previously, long-term (22 months) soy protein consumption 
has been reported to produce no difference in body weight gain in Sprague-Dawley rats 
compared to a casein-based diet [24].  In addition to different dietary proteins, growing female 
PCK rats were fed different amounts and types of n-3 PUFAs in our study.  PCK rats fed 
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soybean oil or 1:1 soybean:salmon oil blend for 12 weeks showed similar body weights (Figure 
1).  Others have reported similar body weight gain in growing rats fed soybean oil, flaxseed oil 
or fish oil [17] [25]. 
Growth disturbances occur early in children with chronic kidney disease [26] and early 
management is required to prevent growth failure and shorter stature [2].  In the current study, 
growing female PCK rats fed SPI with the lipid source as either pure soybean oil or a blend of 
soybean oil and fish oil had no significant differences in femur length (Table 2).  Similarly, 
Sirosis et al. [25] reported femur length was not significantly different for growing female 
Sprague-Dawley rats fed 7% wt fish oil compared to soybean oil.  However, growing female 
Hans:SPRD rats, a model of ADPKD, fed 7% wt flaxseed oil rich in n-3 PUFA, ALA, before the 
onset of disease and continuing for 12 weeks, lengthened the femur compared to rats fed corn oil 
low in ALA [18].  Since ALA content is higher in flaxseed oil compared to soybean oil [27], 
lengthen femur may have been due to feeding a higher ALA dose.  In our study, femur length 
was shorter (P=0.001) in PCK rats fed SPI+SO compared to rats fed Casein + CO and Casein + 
SO (Table 2).  SPI contains isoflavone phytoestrogens [7].  Estrogen receptor beta (ERβ) has 
been shown to be a physiological inhibitor of bone growth in young adult (age four month old) 
female mice [28].  It has been reported that phytoestrogens have binding specificity for ERβ 
[29].  Tou et al. [30] reported that young adult (age 50 d) female Sprague-Dawley rats fed a 
phytoestrogen diet decreased (P<0.05) femur length compared to rats fed Casein+SO diet.  
Therefore, we speculate that decreased femur length in PCK rats fed SPI+SO in this study was 
due to the phytoestrogens in the SPI diet.  However, growing female rats fed SPI+SB diet 
showed no significant differences in femur length compared to casein-fed rats (Table 2).  The 
type of lipid associated with the protein may exert different bone effects.  SPI+SB diet had the 
68 
 
highest n-3:n-6 PUFA ratio as well as EPA and DHA content (Table 1) which has been 
associated with bone growth.  Mechanisms whereby n-3 PUFAs have been suggested to promote 
bone growth include reducing prostaglandin E2 production by decreasing the n-6/n-3 PUFA ratio 
to promote bone formation rate and to inhibit bone resorption, enhancing bone specific alkaline 
phosphatase activity to increase osteoblastic function, and by increasing circulating insulin-like 
growth factor binding protein to promote growth factors [10][31-32]. 
In addition to decreased height, children with kidney diseases often have disordered 
mineral metabolism [1].  The lower sulfur amino acid content of soybean protein compared to 
animal proteins has been suggested to decrease Ca excretion [33].  Growing female PCK rats 
showed no significant differences in Ca excretion; however, urinary P excretion was lower 
(P<0.001) in rats fed the SPI+SB diet despite higher P intake compared to rats fed casein (Table 
3).  Dietary P content was higher in SPI+SO (7.3+0.3 mg) and SPI+SB (7.2+0.3 mg) compared 
to Casein+CO (6.5+0.2 mg) and Casein+SO (6.1+0.5 mg) diets.  Similarly, dietary Ca content 
was higher in SPI+SO (10.0+0.7 mg) and SPI+SB (9.7+0.4 mg) compared to Casein+CO 
(8.2+0.2 mg) and Casein+SO (8.8+0.1 mg) diets.  In turn, higher Ca and P resulted in higher Ca 
and P intake, but there were no significant differences in Ca and P apparent absorption (Table 3).  
PCK rats fed the SPI+SB diet had the highest Ca and P retention.  The SPI+SB diet had the 
highest EPA and DHA content (Table 1).  EPA and DHA alters cell membrane fluidity and this 
may alter intestinal cell membrane fatty acid composition [34].  Along with higher Ca and P 
intake, this may have contributed to higher Ca and P retention in rats fed the SPI+SB diet. 
Despite greater Ca and P retention in rats fed the SPI+SB diet, there were no significant 
differences in long bone Ca or P between the dietary groups (Table 4).  Additionally, there were 
no significant differences in femoral and tibial bone mineral area (BMA), BMC, and BMD 
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(Table 4).  In contrast, Lukas et al. [17] reported that growing female Sprague-Dawley rats fed 
salmon oil for 12 weeks experienced an increase in femur and tibia BMC and BMD.  This 
discrepancy in response may be due to the use of a higher oil dose (12% wt) and the use of pure 
salmon oil compared to the lower dose (7% wt) and soybean oil:salmon oil blend provided to 
growing female PCK rats in this study.  Others have shown in the ADPKD rat model, 
Hans:SPRD-cy rats fed 5% wt flaxseed oil rich in ALA [35] for 8 weeks had no significant effect 
on whole body BMC and BMD.  On the other hand, feeding growing female Hans:SPRD-cy rats 
fed 7% wt flaxseed oil for 12 weeks enhanced whole body BMD and BMC [18].  Flaxseed oil 
contains higher ALA (57%) [23] than soybean oil (7.69%) or soybean:salmon oil blend (4.85%) 
used in the present study (Table 1).  Therefore, higher doses of n-3 PUFA may be necessary in 
order to enhance bone mass in growing female PCK rats. 
Metabolic abnormalities accompanying renal diseases differentially affect cortical and 
trabecular bone that cannot be detected by DXA [36].  Using µCT technology, we found no 
significant differences in trabecular microarchitecture measurements of BV/TV, trabecular 
number, thickness, spacing, connectivity or SMI in growing female PCK rats fed different diets 
(Table 5).  In contrast, growing female Sprague-Dawley rats fed oil sources rich in ALA 
enhanced femur and tibia microarchitecture due to increased bone formation indicated by higher 
serum osteocalcin concentration and no significant differences in bone resorption markers [17].  
In growing female PCK rats, there were no significant differences in serum osteocalcin (Figure 
2A) or the bone resorption marker, urinary DPD (Figure 2B).  In the Lukas et al. [17] study, 
higher doses (12% wt) of pure flaxseed oil or fish oil was provided to Sprague-Dawley rats 
compared to the 7% wt dose oil blend provided to PCK rats in this study.  High fat diets were not 
fed to PCK rats due to reports of worsen polycystic kidney disease progression and severity [37-
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38].  However, the detrimental renal effects of feeding high fat diets were shown to be modulated 
by the dietary lipid source.  Feeding fish oil rich in EPA and DHA reduced renal cysts, whereas 
ALA rich soybean oil and flaxseed oil reduced renal fibrosis in Hans:SPRD-cy rats, a model of 
ADPKD, and in pcy mice, a model of recessive inheritance of PKD [37-38].  Future studies may 
consider high fat diets provided as n-3 PUFAs for early management of bone health and to 
attenuate renal damage, but hypertension and cardiovascular defects are severe complications of 
PKD that also need to be considered when recommending a high fat diet [39-41]. 
In kidney disease, chronic elevated parathyroid hormone preferentially causes cortical 
bone loss [36] [42].  In the present study, there were no significant differences in cortical 
thickness, area, porosity and medullary area in growing female PCK rats fed the different 
experimental diets for 12 weeks (Table 6).  A previous study with growing Sprague-Dawley rats 
showed that feeding oils rich in ALA, EPA, and/or DHA had no effect on cortical bone 
microarchitecture [17].  The main structural determinants of bone mechanical strength include 
width and porosity in the cortical bone; shape, width, connectivity, and anisotropy in the 
trabecular bone [43].  As expected in the absence of significant differences in bone mass and 
trabecular and cortical microarchitecture there were no significant differences in bone strength 
measurements between growing female PCK rats fed the different experimental diets (Table 7).  
In studies reporting enhanced bone mass and microarchitecture with n-3 PUFA consumption, the 
protein source was casein.  Fernandes et al. [8] reported that fish oil reduced bone loss in 
ovariectomized mice particularly in the casein group, but it was unclear whether a synergistic 
effect of soy protein and fish oil on bone existed.  In our study, a casein and soybean oil:salmon 
oil group was not included to assess for synergistic effects between different types of proteins 
and n-3 PUFAs. 
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In summary, to our knowledge this was the first study to investigate diet as a therapeutic 
strategy to promote bone health in PCK rats, an animal model of ARPKD.  We focused on 
dietary n-3 PUFA and SPI since current general dietary guidelines to promote a healthier 
population include increasing consumption of plant proteins and n-3 PUFAs [44].  Growing 
female PCK rats fed the SPI+SB diet increased Ca and P retention, however bone mineralization 
was not significantly enhanced at 12 weeks feeding.  A longer feeding duration and/or the use of 
pharmalogical doses may be required in order to enhance bone mineralization.  All diets equally 
supported body weight gain and produced no greater or worse long bone mass, 
microarchitecture, and strength, but may influence other renal disease complications of 
longitudinal bone growth and mineral metabolism indicated by effects on femur length and 




ADPKD, autosomal recessive polycystic kidney disease; AIN-93G, American Institute of 
Nutrition-93G; ALA, alpha-linolenic acid; ANOVA, analysis of variance; ARPKD, autosomal 
recessive polycystic kidney disease; BMA, bone mineral area; BMC, bone mineral content; 
BMD, bone mineral density; BV/TV, bone volume per unit of total volume; Ca, calcium; CO2, 
carbon dioxide; ddH2O, deionized distilled water; DPD, deoxypyridinoline; DHA, 
docosahexaeonic acid; DXA, dual energy X-ray absorptiometry; EIA, enzyme immunoassay; 
EPA, eicosapentaenoic acid; ERβ, estrogen receptor beta; ESRD, end stage renal disease; ICP, 
inductively coupled plasma spectrometry; LA, linoleic acid; n-3 PUFA, omega-3 
polyunsaturated fatty acids; n-6 PUFA, omega-6 polyunsaturated fatty acids; µCT, micro-
computed tomography; PBM, peak bone mass; PKD, polycystic kidney disease; P, phosphorus; 
SB, soybean oil:salmon oil blend; SEM, standard error of the mean; SPI, soy protein isolate; 
SMI, structure model index; SO, soybean oil; TbN; trabecular number, TbTH, trabecular 
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Figure 1.  The effect of feeding growing PCK female rats soy protein isolate and/or omega-3 
polyunsaturated fatty acids on body weight during the 12 week feeding study.  Values are the 
mean + SEM of n=12 rats/diet group.  Abbreviations are casein + corn oil (Casein + CO), 
casein + soybean oil (Casein + SO), soy protein isolate + soybean oil (SPI +SO) or soy 
protein isolate + 1:1 soybean/salmon oil (SPI + SB). 
 
Figure 2.  The effect of feeding growing PCK female rats on soy protein isolate and/or 
omega-3 polyunsaturated fatty acids on body weight for 12 weeks on A) serum osteocalcin 
concentrations and B) urinary deoxypyridinoline.  Bars represent the mean+SEM of n=10 
rats/diet group.  Abbreviations are casein + corn oil (Casein + CO), casein + soybean oil 
(Casein + SO), soy protein isolate + soybean oil (SPI +SO) or soy protein isolate + 1:1 










Casein + CO Casein + SO SPI + SO SPI + SB 
Casein 200.0 200.0 0.0 0.0 
Soy protein isolate 0.0 0.0 200.0 200.0 
L-Cystine 3.0 3.0 1.3 1.3 
Corn Starch 397.5 397.5 397.5 397.5 
Maltodextrin 132.0 132.0 132.0 132.0 
Sucrose 100.0 100.0 100.0 100.0 
Soybean Oil 70.0 0.0 70.0 35.0 
Corn Oil 0.0 70.0 0.0 0.0 
Salmon Oil 0.0 0.0 0.0 35.0 
Cellulose 50.0 50.0 50.0 50.0 
Mineral Mix
2 
35.0 35.0 35.0 35.0 
Vitamin Mix
2 
10.0 10.0 10.0 10.0 
Choline bitartrate 2.5 2.5 2.5 2.5 
TBHQ, antioxidant 0.014 0.014 0.014 0.014 
Calories 377 377 377 377 
     
Fatty acids (%)     
n-3 PUFAs     
Alpha-linolenic acid (ALA, 18:3n-3) 0.59+0.18c 7.69+0.02a 7.68+0.04a 4.85+0.01b 
Eicosapentaenoic acid (EPA, 20:5n-3) ND ND ND 7.4+0.03 
Docosahexaenoic acid (DHA, 22:6n-3) ND ND ND 3.9+0.1 
n-6 PUFAs     
Linoleic acid (LA, 18:2n-6) 52.93+2.68a 55.78+0.07a 56.09+0.09a 35.19+0.06b 
Arachidonic acid (ARA, 20:4n-6) 1.10+0.04a 0.16+0.005c 0.21+0.01c 0.41+0.007b 
n-3/n-6 0.01 0.14 0.14 0.44 
1
All ingredients are from Harlan Teklad except for SPI from DuPont Nutrition and Health (St. 
Louis, MO) and salmon oil from JEdwards International (Quincy, MA). 
2
Based on the AIN-93G vitamin and mineral mixes [45].  Different superscript letters a, b, c 
within the same rows indicate significant differences at P<0.05 by one-way ANOVA followed 
by Tukey’s test.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy protein isolate; SB, 
soybean oil:salmon oil blend; TBHQ, tertiary butylhydroquinone; ND, not detectable.
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*Values are the means +SEM of n=12 rats/group.  Different superscript letters a, b within the same rows indicate significant 
differences at P<0.05 by one-way ANOVA followed by Tukey’s test.  Abbreviations are CO, corn oil; SO,  
soybean oil; SPI, soy protein isolate; SB, soybean oil:salmon oil blend.
Measurement* Casein + CO Casein + SO SPI + SO SPI + SB P-value 
Femur 
Length (cm) 31.01 ± 0.13 b 31.23 ± 0.15 b 30.17 ± 0.28 ab 30.74 ±0.14 a 0.001 
Medial Lateral width (mm) 3.77 ± 0.02 3.75 ± 0.03 3.78 ± 0.02 3.79 ± 0.03 0.78 
Anterior posterior width (mm) 2.78 ± 0.03 2.77 ± 0.03 2.75 ± 0.03 2.84 ± 0.03 0.22 
Dry weight (g) 0.69 ± 0.04 0.70 ± 0.04 0.68 ± 0.46 0.68 ± 0.04 0.98 
Tibia      
Length (cm) 36.24 ± 0.15 36.45 ±0.07 36.20 ± 0.07 36.17 ± 0.11 0.25 
Medial Lateral width (mm) 2.24 ± 0.02 2.29 ± 0.02 2.24 ± 0.02 2.29 ± 0.02 0.18 
Anterior posterior width (mm) 2.68 ± 0.02 2.67 ± 0.02 2.67 ± 0.02 2.66 ± 0.02 0.88 
Dry weight (g) 0.47 ± 0.02 0.48 ± 0.02 0.46 ± 0.02 0.47 ± 0.02 0.95 
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Values are expressed as the mean ± SEM of n=10 rats/group. Different letters a, b within the same column indicate significant 
differences at P<0.05 by one-way ANOVA followed by Tukey’s test.  Abbreviations are SO, soybean oil; SPI, soy protein isolate; 
SB, soybean oil:salmon oil blend; Ca, calcium, P, phosphorus. 
1
Calcium apparent absorption was calculated as [(Ca intake – fecal Ca excretion)/Ca intake] x 100. 
2
Calcium retention was determined by calculating [Ca intake – (fecal Ca excretion + urinary Ca excretion)]. 
3
Phosphorus apparent absorption was calculated as [(P intake – fecal P excretion)/P intake] x 100. 
4
Phosphours retention was determined by calculating [P intake – (fecal P excretion + urinary P excretion)]. 
Measurement* Casein + CO Casein + SO SPI + SO SPI + SB P-value 
Calcium      
Ca Intake (g/d) 131.8 ± 2.4b 123.4 ± 2.2b 145.3 ± 2.1a 150.0 ± 2.4a <0.001 
Fecal Ca Excretion (mg/d) 29.9 ± 2.3 25.8 ± 2.9 34.0 ± 3.0 29.0± 2.7 0.23 
Urinary Ca Excretion/Creatinine 
(mg/dl) 
2.5± 0.5 2.6± 0.9 1.1± 0.1 2.2± 0.5 0.18 
Ca Apparent Absorption (%)
1 
77.2± 1.7 79.0± 2.4 76.5± 2.1 80.6± 1.8 0.46 
Ca Retention (mg/d)
2 
1.6 ± 0.3b 2.2 ± 0.3b 4.5 ± 0.7a 4.6 ± 1.0a 0.004 
Phosphorus      
P Intake (g) 92.0± 1.0b 96.5 ± 2.1b 109.9 ± 2.0a 108.7 ± 2.3a <0.001 
Fecal P Excretion (mg/d)
3 
26.1 ± 2.6 22.3 ± 3.1 34.0 ± 3.0 26.3± 2.7 0.05 
Urinary P Excretion/Creatinine 
(mg/dl)
4 
10.6± 1.0a 10.8± 2.1a 7.3± 1.0ab 3.5± 0.9b <0.001 
P Apparent Absorption (%) 71.6 ± 2.9 77.0 ± 3.2 69.0 ± 2.8 75.7 ± 2.5 0.18 
P Retention (mg/d) 0.09± 0.008b 0.12 ± 0.007b 0.14 ± 0.01ab 0.15 ± 0.02a 0.01 
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Table 4.  Bone Mineralization in Growing Female PCK Rats Fed Different Diets. 
 
*Values are the means +SEM of n=12 rats/group.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy protein isolate; SB, 











Ca (mg/mg bone) 9.07 ± 0.17 9.30 ± 0.10 9.43 ± 0.07 9.40 ± 0.150 0.23 
P (mg/mg bone) 4.90 ± 0.09 5.01 ± 0.05 5.05 ± 0.04 5.05 ± 0.07 0.39 
Ash (mg/mg bone) 0.061 ± 0.001 0.058 ± 0.001 0.060 ± 0.001 0.061 ± 0.001 0.66 
BMA (cm
2
) 1.30 ± 0.01 1.29 ± 0.02 1.28 ± 0.01 1.30 ± 0.01 0.27 
BMC (g) 0.23 ± 0.0001 0.23 ± 0.0002 0.22 ± 0.0001 0.23 ± 0.0001 0.67 
BMD (mg/cm
2
) 0.18 ± 0.0001 0.18 ± 0.0002 0.17 ± 0.0001 0.18 ± 0.0002 0.35 
Tibia      
Ca (mg/mg bone) 9.30 ± 0.11 9.07 ± 1.20 9.68 ± 0.25 9.55 ± 0.19 0.14 
P (mg/mg bone) 4.83 ± 0.06 4.68 ± 0.09 4.99 ± 0.13 4.95 ± 0.10 0.12 
Ash (mg/mg bone) 0.060 ± 0.001 0.059 ± 0.001 0.059 ± 0.002 0.061 ± 0.0012 0.59 
BMA (cm
2
) 1.54 ±0.04 1.50 ± 0.06 1.56 ± 0.06 1.49 ± 0.04 0.56 
BMC (g) 0.33 ± 0.01 0.32 ± 0.01 0.33 ± 0.01 0.31 ± 0.02 0.48 
BMD (mg/cm
2




Table 5.   Trabecular Bone Microarchitecture in Growing Female PCK Rats Fed Different Diets. 
 
Measurement Casein + CO Casein + SO SPI + SO SPI + SB P-value 
Femur      
BV/TV (%) 14.30 ± 0.54 14.00 ± 0.58 12.95 ± 0.96 13.64 ± 0.86 0.61 
TbN (per mm) 2.87 ± 0.11 2.74 ± 0.11 2.77 ± 0.20 2.86 ± 0.10 0.87 
TbTh (mm) 0.07 ± 0.0009 0.07 ± 0.001 0.06 ± 0.001 0.07 ± 0.002 0.18 
TbSp (mm) 0.36 ± 0.01 0.38 ± 0.01 0.40 ± 0.04 0.36 ± 0.01 0.65 
Conn (1/mm
3
) 80.77 ± 2.99 76.47 ± 2.83 77.06 ± 5.26 77.83 ± 3.59 0.86 
SMI 2.28 ± 0.03 2.30 ± 0.05 2.12 ± 0.06 2.36 ± 0.07 0.31 
Tibia      
BV/TV (%) 9.43 ± 0.62 9.67 ± 0.63 9.13 ± 0.84 9.24 ± 0.83 0.96 
TbN (per mm) 2.51 ± 0.13 2.44 ± 0.17 2.39 ±0.19 2.61 ± 0.16 0.82 
TbTh (mm) 0.06 ± 0.001 0.06 ± 0.0009 0.06 ± 0.001 0.06 ± 0.001 0.33 
TbSp (mm) 0.42 ± 0.02 0.44 ± 0.30 0.46 ± 0.05 0.41 ± 0.03 0.63 
Conn (1/mm
3
) 43.00 ± 4.56 43.58 ± 4.59 43.53 ± 6.11 43.26 ± 6.34 1.00 
SMI 2.85 ± 0.05 2.80 ± 0.04 2.88 ± 0.07 2.88 ± 0.07 0.72 
*Values are expressed as the mean ± SEM of n=12 bones/group.   Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy protein 
isolate; SB, soybean oil:salmon oil blend, BV/TV, trabecular bone volume per unit of total volume; TbN, trabecular number; TbTh, 





























*Values are expressed as the mean ± SEM of n=12 bones/group.  Abbreviations are are CO, corn oil; SO, soybean oil; SPI, soy 
protein isolate; SB, soybean oil:salmon oil. 
Measurement Casein + CO Casein + SO SPI + SO SPI + SB P value 
Femur      
Medullary Area (mm
2
) 0.26 ± 0.006 0.25 ± 0.007 0.25 ± 0.006 0.26 ± 0.007 0.94 
Cortical Thickness (mm) 0.55 ± 0.008 0.55 ± 0.004 0.56 ± 0.004 0.55 ± 0.004 0.47 
Cortical Area (mm
2
) 4.49 ± 0.03 4.40 ± 0.05 4.56 ± 0.03 4.52 ± 0.05 0.06 
Porosity (%) 5.42 ± 0.12 5.45 ± 0.15 5.28 ± 0.14 5.39 ± 0.12 0.78 
Tibia      
Medullary Area (mm
2
) 0.20 ± 0.004 0.19 ± 0.003 0.18 ± 0.004 0.19 ± 0.005 0.46 
Cortical Thickness (mm) 0.52 ± 0.004 0.53 ± 0.003 0.53 ± 0.01 0.53 ± 0.006 0.59 
Cortical Area (mm
2
) 2.90 ± 0.03 2.94 ± 0.03 2.88 ± 0.05 2.98 ± 0.04 0.29 
Porosity (%) 6.32 ± 0.02 6.06 ± 0.09 6.11 ± 0.13 6.04 ± 0.16 0.37 
85 
 
Table 7.  Bone Strength Measurements in Growing Female PCK Rats Fed Different Diets. 
Measurement Casein + CO Casein + SO SPI + SO SPI + SB P-value 
Femur      
Peak Force (N) 42.48 ± 2.67 37.19 ± 2.62 40.41 ± 2.57 44.47 ± 3.05 0.26 
Ultimate Stiffness (N/S) 4.29 ± 0.36 4.29 ± 0.23 3.78 ± 0.33 4.21 ± 0.29 0.63 









11.49 ± 1.04 11.39 ± 0.53 10.20 ± 0.98 10.97 ± 0.97 0.75 
Tibia      
Peak Force (N) 22.30 ± 1.72 19.23 ± 1.29 19.98 ± 1.72 20.73 ± 1.34 0.57 
Ultimate Stiffness (N/S) 1.68 ± 0.13 1.75 ± 0.13 1.58 ± 0.11 1.56 ± 0.08 0.61 









19.33 ± 1.70 19.02 ± 1.64 17.81 ± 1.23 17.32 ± 4.90 0.76 
*Values are expressed as the mean ± SEM of n=12 bone pairs/group.  Abbreviations are CO, 





















5.0     Chapter 3:  
The Effect of Omega-3 Polyunsaturated Fatty Acid and/or Soy Protein Isolate Supplementation 
on Attenuating the Progression of Polycystic Liver Disease as a Complication of Polycystic 
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5.1.  Abstract 
Polycystic Liver Disease (PLD) is characterized by multiple cyst formation leading to 
increased liver size, structural damage, and loss of function.  Feeding soy protein isolate has been 
shown to decrease cystic growth and proliferation, dietary omega-3 polyunsaturated fatty acids 
(n-3 PUFAs) have been reported to have anti-inflammatory actions.  Therefore, the objective of 
this study was to investigate whether soy protein isolate (SPI) and/or n-3 PUFA supplementation 
attenuates PLD progression.  Young (age 28 d) female pck rats were fed diets (n=12/group) 
consisting of casein + corn oil (Casein + CO), casein + soybean oil (Casein + SO), SPI + 
soybean oil (SPI + SO), or SPI + 1:1 soybean/salmon oil blend (SPI + SB).  Liver weights were 
not significantly different among the diet treatment groups.  Histological evaluation of the liver 
showed that rats fed SPI+SB diet had the highest (P=0.03) cyst obstruction.  Rats fed SPI+SB 
diet also had the highest (P < 0.001) interstitial portal inflammation.  Gene expression by real 
time quantitative polymerase chain reaction (RT-qPCR) showed no significant differences in 
inflammation factors.  Female pck rats fed SPI and/or n-3 PUFAs showed no significant 
differences in histological evidence of fibrosis or gene expression of liver fibrosis.  However, 
rats fed SPI + SB diet had the highest liver total lipid (P < 0.001) and steatosis (P = 0.003) 
indicating fatty liver.  Based in the results, none of the dietary treatments attenuated disease 
progression.  Furthermore, the supplementation of SPI +SB diet increased PLD liver steatosis 
and inflammation.  
 




5.2.  Introduction 
  Polycystic liver disease (PLD) is a genetic disorder characterized by the presence of 
multiple benign cysts that accumulate on the epithelial lining of the liver as a complication of 
either autosomal dominant or autosomal recessive polycystic kidney disease (PKD).
1
  In PKD, 
there are genetic mutations in the PKD1, PKD2, or PKHD1 genes, which cause cyst growth and 
progression in the kidneys and liver.  Female patients with advanced PKD exhibit greater liver 
cyst progression and severity compared to males.
1
  While the initial stages of PLD are 
asymptomatic, clinical symptoms associated with PLD include abdominal pain/swelling, 
bleeding into cysts, cyst infection, and jaundice due to bile duct obstruction.
2
  Furthermore, cyst 
accumulation may alter metabolism in the liver.
3
  Currently, there are no gene therapy or 
efficacious pharmaceutical treatment for PLD.  Surgical aspiration of cysts is the main short-term 
treatment used to alleviate pressure due to cysts.
4
 
Dietary treatment is a potentially safe, cost-effective, and non-invasive option that may 
benefit PLD patients.  Studies have investigated the role of diet therapy in PKD which is 
commonly associated with PLD.
5
 Feeding soy protein isolate (SPI) in female PKD animal 
models has been shown to decrease cystic growth and overall cyst proliferation.
6,7
  Feeding SPI 
also decreased inflammation as indicated by decreased renal cyclooxygenase (COX-2) enzyme 
activity.
7
  Increasing omega-3 polyunsaturated fatty acids (n-3 PUFAs) is another dietary 
component with the potential to decrease inflammation and attenuate disease progression.  
Dietary n-3 PUFAs have been reported to have anti-inflammatory actions by altering tissue fatty 
acid composition, eicosanoid production, transcription factors, and gene expression.
8,9
  Several 
studies have reported that feeding PKD rodent models diets supplemented with n-3 PUFAs 
significantly reduced renal inflammation and cystic damage.
10,11
  Since cyst pathogenesis in the 
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liver is similar to PKD these diet components may attenuate PLD.  To our knowledge, no studies 
have examined the role of soy protein isolate or n-3 PUFAs on PLD progression and severity.  
Few PKD animal models exhibit characteristics of PLD despite liver cysts being the most 
common extra-renal manifestation of PKD.
12
  The pck rat model resembles a slow progression 
ADPKD and PLD.
13
  The pck rat model shows cystogenesis, cyst enlargement and liver bile duct 
dilation within one week of age.
12
  Therefore, making the pck rat an attractive model to 
determine the potential for dietary intervention.  Females are at higher risk for developing PLD 
than males,
1
 therefore it is important to examine dietary treatments in female rodent models.  The 
objective of this study was to determine the role of soy protein and/or n-3 PUFAs on PLD 
progression and severity in female pck rats. 
5.3.  Methods 
 Animals and diets 
 All animal procedures performed in this study were conducted in accordance with the 
National Research Council for the Care and Use of Laboratory Animals Guidelines
14
 and were 
approved by the Animal Care and Use Committee at West Virginia University.  Young (age 28 
day) female pck rats were purchased from Charles River Laboratories (Wilmington, MA).  All 
rats were individually caged and maintained in a room kept at 21°C with a 12 hour light/dark 
cycle throughout the 12 week study period.  Following acclimation, animals were randomly 
assigned (n=12 rats/group) to different experimental diets based on the American Institute of 
Nutrition-93G (AIN-93 G) diet.  A standard diet consisting of purified ingredients and 
formulated to meet all the nutritional requirements for growing rats as defined by the National 
Research Council.
14






Casein + CO Casein + SO SPI + SO SPI + SB 
Casein 200.0 200.0 0.0 0.0 
Soy protein isolate 0.0 0.0 200.0 200.0 
L-Cystine 3.0 3.0 1.3 1.3 
Corn Starch 397.5 397.5 397.5 397.5 
Maltodextrin 132.0 132.0 132.0 132.0 
Sucrose 100.0 100.0 100.0 100.0 
Soybean Oil 70.0 0.0 70.0 35.0 
Corn Oil 0.0 70.0 0.0 0.0 
Salmon Oil 0.0 0.0 0.0 35.0 
Cellulose 50.0 50.0 50.0 50.0 
Mineral Mix
2 
35.0 35.0 35.0 35.0 
Vitamin Mix
2 
10.0 10.0 10.0 10.0 
Choline bitartrate 2.5 2.5 2.5 2.5 
TBHQ, antioxidant 0.014 0.014 0.014 0.014 
Calories 377 377 377 377 
     
Fatty acids (%)     
n-3 PUFAs     
Alpha-linolenic acid (ALA, 18:3n-3) 0.59+0.18c 7.69+0.02a 7.68+0.04a 4.85+0.01b 
Eicosapentaenoic acid (EPA, 20:5n-3) ND ND ND 7.4+0.03 
Docosahexaenoic acid (DHA, 22:6n-3) ND ND ND 3.9+0.1 
n-6 PUFAs     
Linoleic acid (LA, 18:2n-6) 52.93+2.68a 55.78+0.07a 56.09+0.09a 35.19+0.06b 
Arachidonic acid (ARA, 20:4n-6) 1.10+0.04a 0.16+0.005c 0.21+0.01c 0.41+0.007b 
1
All ingredients are from Harlan Teklad except for SPI from DuPont Nutrition and Health (St. 
Louis, MO) and salmon oil from Jedwards International (Quincy, MA). 
2
Based on the AIN-93G vitamin and mineral mixes.  Different superscript letters a, b, c within 
the same rows indicate significant differences at P<0.05 by one-way ANOVA followed by 
Tukey’s test.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy protein isolate; SB, 1:1 
soybean oil:salmon oil blend; TBHQ, tertiary butylhydroquinone; ND, not detectable. 
 
The protein sources consisting of 200 g/kg diet as either casein or soy protein isolate 
(SPI).  SPI was generously provided by DuPont Nutrition and Health (St. Louis, MO).  The lipid 
sources consisted of 70 g/kg diet as either corn oil which is low in n-3 PUFAs, soybean oil which 
contains the essential fatty acids linoleic acid (LA, 18:2n-6) and alpha-linolenic acid (ALA, 
18:3n-3) or salmon oil which is rich in the long-chain n-3 PUFAs, eicosapentaenoic (EPA, 
20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) as a 1:1 soybean oil + salmon oil blend.  
Salmon oil was purchased from Jedwards International Inc (Quincy, MA).  The experimental 
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diets consisted of: casein + corn oil (Casein + CO), casein + soybean oil (Casein + SO), soy 
protein isolate + soybean oil (SPI +SO) or soy protein isolate + 1:1 soybean/salmon oil (SPI + 
SB). 
Rats were provided free access to water and diet.  To prevent variability in food intake, 
rats were provided 15 ± 2 g of powdered diet daily based on previous studies showing growing 
female rats consume 15 g powdered diet/d (Tou et al 2011).15  All diets were kept at -20oC until 
fed.  Fresh diet was provided daily.  At the end of the 12-week feeding study, rats were 
euthanized by CO2 inhalation.  Liver was excised, weighed, immediately frozen in liquid 
nitrogen, and stored at −80 °C for fatty acid and molecular analysis.  The left lateral liver lobes 
were immediately fixed in a 10% formalin solution for histological evaluation. 
  Histological evaluation of liver morphometry  
The left lateral liver lobes (n=11-12) were dehydrated through a series of increasing 
ethanol concentrations (70-100% in ddH2O) then placed in xylene.  The tissues were embedded 
in paraffin and serially cut to 8 µm thick sections using a microtome (American Optical 
Company, NY).  The paraffin embedded sections were placed on glass slides for mounting.  
Mounted sections were then de-paraffinized in xylene, and rehydrated through a series of 
decreasing ethanol concentrations (100-70%) prior to staining. Tissue slides were stained with 
hematoxylin and eosin to analyze renal cyst number and size (0.3–1.0 mm) and structural 
abnormalities.  All slides were analyzed using a Nikon TE 2000-S light microscope (Nikon 
Instruments, NY) at 4X magnification by a pathologist blinded to the dietary treatments.  Images 
were captured using a PC interfaced with Q-Capture imaging software (Quantitative Imaging 
Corporation, BC, Canada). 
  Analysis of liver fatty acid composition 
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Total lipid was extracted from snap frozen liver tissue according to a modified method of 
Bligh and Dyer.
16
  Briefly, frozen liver tissue (~400 mg) was homogenized in Tris/EDTA buffer 
(pH 7.4) and nonadecenoic (19:1) added as an internal standard.  Hepatic tissue was 
homogenized in chloroform: methanol:acetic acid (2:1:0.15 v/v/v) solution, centrifugation at 900 
g for 10 min at 10°C, and the bottom chloroform layer was collected.  The collected chloroform 
was filtered through 1-phase separation filters and then dried under nitrogen gas. 
The extracted lipid samples were transmethylated according to Fritsche and Johnston.
17
  
Briefly, extracted fatty acids were methylated by adding 4% H2SO4 in anhydrous methanol to the 
dried extracted lipid samples followed by incubation in a 90°C water bath for 60 min.  Samples 
were cooled to room temperature and 3 mL of ddH2O was added.  Chloroform was added to the 
methylated samples and centrifuged at 900 g for 10 min at 10°C, the chloroform layer was 
collected, and filtered through anhydrous Na2SO4.  Samples were dried under nitrogen gas and 
diluted in iso-octane. 
Fatty acid methyl esters (FAME) samples were analyzed by gas chromatography (CP-
3800, Varian, CA) using an initial temperature of 140°C held for 5 minutes and then increased 
1°C per minute to a final temperature of 220°C.  A wall-coated open tubular fused silica 
capillary column (Varian Inc., Walnut Creek, CA) was used to separate FAMEs with CP-Sil 88 
as the stationary phase.  Nitrogen was used as the carrier gas and total separation time was 110 
min. Quantitative 37 Component FAME Sigma Mix (Supelco, Bellefonte, PA) was be used as a 
standard to identify fatty acids.  Fatty acids were quantified using peak area counts and retention 
time.  All samples were performed in duplicate and reported as % total fatty acids. 
  RNA isolation and gene expression analysis 
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Total renal RNA was extracted from ~100 mg of frozen liver tissue following the Total 
RNA Isolation procedure of the mirVana miRNA Isolation Kit (Ambion, TX).  Isolated RNA 
integrity was visualized on a 1.5% agarose gel and isolated RNA concentration was quantified 
by spectrophotometry (Thermo Scientific, DE).  After DNase treatment of the isolated RNA 
(Applied Biosystems, CA), total mRNA was amplified using the Superscript III First Strand 
Synthesis assay with oligo dT primers (Invitrogen, CA). 
Primer efficiencies were determined on pooled RNA samples serially diluted in ddH2O 
up to 1:10000.  PCR consisted of 2.5µl of SYBR
®
 Green Master Mix (Applied Biosystems, CA), 
1µl of cDNA, 1µl of respective forward and reverse primers, and 0.5µl of ddH2O for a total 
reaction volume of 5µl.  The thermal profile consisted of 50°C for 2 minutes, 95°C for 10 
minutes, and then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.  Primers were 
designed for rat cyclooxygenase -2 (COX-2), mammalian target of rapamycin (mTOR), mitogen-
activated protein kinase (MapK), peroxisome proliferator-activated receptor gamma (PPARγ), 
transforming growth factor beta 1 (Tgfβ1), epidermal growth factor (Egf), somatostatin receptor 
3 (Sstr3), nuclear factor, erythroid derived 2, like 2 (Nrf2), cystic fibrosis transmembrane 
conductase regulator (Cftr), angiotensin II (At1), nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha (Ikbα), tumor necrosis factor alpha (TNFα) and the 
housekeeping gene beta actin (ActB) using the Primer3 program (Howard Hughes Medical 
Institute) and respective mRNA sequences obtained from NCBI.  Forward and reverse primers 






All primers were normalized to beta actin. 
  Serum clinical markers of liver function 
Rats were euthanized by CO2 inhalation and blood collected by aorta puncture.  Blood 
was centrifuged at 1,500 g for 10 min at 4 °C to obtain serum.  Serum measures of liver function 
included: gamma-glutamyl transferase, alanine aminotransferase, albumin, cholesterol, total 
protein, and triglycerides.  Values were determined enzymatically using a commercially 
available Vet-16 rotor and quantified by a Hemagen Analyst automated spectrophotometer 
(Hemagen Diagnostics Inc., Columbia, MD). 
  Statistical analysis 
Results are expressed as means ± standard error of the mean (SEM).  One-way analysis 
of variance (ANOVA) was used to determine differences among treatment groups.  Post-hoc 
multiple comparisons were performed using Tukey's test.  Differences were considered 
significant at P<0.05.  All statistical analyses were performed using SigmaStat 3.1 statistical 
software program (Systat Software Inc., San Jose, CA).  Relative gene expression was calculated 
according to methods by Bari et al,
18
 with values obtained by calculating 40-DCt.  DCt was 
Gene Forward Primer Reverse Primer 
COX-2 5’ CGGAGGAGAAGTGGGTTTTAG 3’ 5’ TGAAAGAGGCAAAGGGACAC 3’ 
mTOR 5’ GGCTTCAACAGCAAGGACAC 3’   5’ ACGGGTGAGGTAACAGGATG 3’ 
mapK 5’CGTTCAGATGTCGGTGTCC 3’  5’CGGCTCAAAGGAGTCAAGAG 3’ 
PPARγ 5’ TGGAGCCTAAGTTTGAGTTTGC 3’ 5’CAGCAGGTTGTCTTGGATGTC 3’ 
Tgfβ1 5’ TGGAGCCTGGACACACAGTA 3’  5’ GTAGTAGACGATGGGCAGTGG 3’ 
Egf 5’ TGGTGTCTGTCTGTGTGGTG 3’ 5’ GGGCTGTTGGTGTTCCTCTA 3’ 
Sstr3 5’ CTTCCTCTCCTACCGCTTCA 3’  5’ CCTCCTCCTCCGTCTTCTCT 3’ 
Nrf2 5’ TGACTCGGAAATGGAAGAGC 3’ 5’ TGTGTTGGCTGTGCTTTAGG 3’ 
Cftr 5’ ACACGCACACGCACACTAAT 3’ 5’ GCTTTCACGGGCATAGGTAG 3’ 
At1 5’ TTGAGGTGGAGTGACAGGTTC 3’ 5’ ATGGTCCTTTGGTCGTAAGC 3’ 
Iκbα 5’ CTGGTCTCGCTCCTGTTGA 3’  5’ GCCCTGGTAGGTTACTCTGTTG 3’ 
Tnfα 5’ CACAAGGCTGAAGATGT 3’ 5’ GAGGGAAGGAAGGAAGGAAG 3’ 
Actβ 5’ TTGCTGACAGGATGCAGAAG 3’ 5’ CAGTGAGGCCAGGATAGAGC 3’ 
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calculated as the difference in threshold cycle (Ct) of the gene of interest and the reference gene 
(ActB) while the number 40 was selected because it represents the highest Ct value.  Following 
the 40-DCt calculation, gene expression was analyzed using a one way ANOVA.   
5.4.  Results 
  Body weight and liver mass 
There were no significant differences in body weight gain for rats fed Casein + CO 
(184.25 ± 6.36 g), Casein +SO (184.42 ± 4.92 g), SPI+SO (175.58 ± 4.84 g) and SPI+SB diets 
(186.00 ± 13.15 g).  There were also no significant differences in final body weight for rats fed 
Casein+CO (271.25 ± 2.03 g), Casein +SO (270.50 ± 2.82 g), SPI+SO (281.45 ± 9.42 g) and 
SPI+SB (269.0 ± 3.63 g) diets.  There were no significant differences in absolute or relative liver 
weights (Table 2). 
  Liver histology 
Figure 2A-C are representative H&E staining of liver cysts, inflammation, and steatosis.  
Although cyst effacement was observed in all groups, there were no significant differences 
among the dietary treatments (Table 1).  Rats fed SPI + SB diet had significantly higher cyst 
obstruction compared to rats fed Casein + CO or SPI + SO diet.  Cyst obstruction was not 
observed in rats fed Casein + SO diet.  Steatosis was highest (P < 0.03) in rats fed SPI + SB diet.  
Rats fed Casein + SO and SPI + SO diet had significantly higher steatosis than rats fed Casein + 
CO diet.  Although no differences were seen in portal fibrosis among the treatment groups, portal 
inflammation was highest (P < 0.03) in rats fed SPI + SB diet.  
  Hepatic tissue fatty acid composition 
Total lipid content was highest (P<0.05) in rats fed SPI + SB diet.  Rats fed Casein + SO, 
SPI + SO, and SPI + SB diets had higher (P< 0.001) hepatic tissue ALA content than rats fed 
99 
 
Casein + CO diet.  Hepatic tissue EPA content was highest (P < 0.001) in rats fed SPI + SB diet.  
Rats fed SPI + SB diet had the highest (P< 0.001) hepatic DHA content.  Rats fed SO as the 
lipid source had similar hepatic DHA content regardless of the protein source.  Rats fed Casein + 
CO diet had the lowest (P< 0.001) renal DHA content (Table 2).  There were no significant 
differences in tissue renal linoleic acid (LA, 18:2n-6) content among the diet treatment groups.  
Hepatic arachidonic acid (AA, 20:4n-6) content was lowest (P < 0.001) in rats fed the SPI + SO 
diet (Table 2).   
  Hepatic gene expression analysis 
There were no significant differences hepatic relative gene expression between rats fed 
the different diets (Table 4). 
  Biomarkers of liver function 
There were no significant differences in liver function measurements of gamma-glutamyl 
transferase, alanine aminotransferase, albumin, or total protein among the diet treatment groups 
(Table 3).  Rats fed the Casein + CO diet had the highest (P < 0.001) serum cholesterol 
concentration, while rats fed SO as a lipid source had similar serum cholesterol levels.  Rats fed 
the SPI + SB diet had the lowest (P < 0.01) serum cholesterol levels.  Serum triglycerides were 
below detected levels. 
5.6.  Discussion 
PLD patients are mostly asymptomatic, but as the disease progresses, multiple cyst 
formation eventually leads to a loss of liver structure, function, and altered metabolism.
3
  
Increases in tissue size are often indicative of increased cyst formation and progression.
19
  In the 
present study, absolute and relative liver weights were similar among the dietary treatment 
groups.  Histological evaluation showed all rats had liver cyst accumulation regardless of the 
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dietary treatment group.  Although, no significant differences were observed in cyst effacement, 
rats fed SPI + SB diet had significantly increased cyst obstruction compared to the other dietary 
treatment groups.  Cyst obstruction may prevent transport of lipids from the liver into the 
circulation.  In the present study, rats fed SPI + SB diet had significantly higher hepatic total 
lipid content than the rats fed other dietary treatments.  Histological evaluation showed that rats 
fed the SPI + SB diet had significantly increased steatosis compared to all other dietary 
treatments.  The development of hepatic steatosis results from an imbalance in the rates of entry, 
synthesis, or clearance of lipids from the liver.
27
   
Rats fed SPI + SB diet consisting of a 7% wt lipids as a 1:1 soybean oil: fish oil blend 
also had reduced serum cholesterol (P < 0.001) compared to other dietary treatments.  Similarly, 
M-Shirazi et al
20
 showing that female Wistar rats fed 7% wt fish oil exhibited significantly 
increased hepatic steatosis and decreased serum cholesterol compared to rats fed soybean oil.  
These results indicate that fish oil may not be fully metabolized in the liver thus, inducing 
hepatic steatosis.  In female LDLR
-/-
 mice, the inclusion of fish oil dose resulted in increased 
cholesterol storage capacity within the liver.
21
 This may explain lower serum cholesterol on a 
fish oil diet and higher total lipid content and liver steatosis.  
Studies have suggested that EPA and DHA are beneficial for the treatment of liver 
inflammation associated with hepatic lipid accumulation.
22





 mice, a model nonalcoholic fatty liver disease, fed diets rich in DHA had 
significantly reduced hepatic inflammation and fibrosis compared to mice fed diets rich in olive 
oil and EPA.  The authors suggested that n-3 PUFAs could be used as dietary treatment for 
individuals with altered lipid metabolism disorders by attenuating inflammation and fibrosis.
23
  
In the present study, rats fed Casein + SO, SPI + SO, and SPI + SB diets had similar (P < 0.001) 
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hepatic ALA content.  ALA can be converted to the long chain omega-3 fatty acids EPA and 
DHA, however conversion in mammals is low.
24
  Therefore, rats fed SPI + SB diet containing 
pre-formed EPA and DHA had the highest (P < 0.001) EPA and DHA hepatic content.  The 
increase in hepatic omega-3 (EPA and DHA) content replaces tissue n-6 fatty acids.  Rats fed 
SPI+SB diet had the lowest (P < 0.001) hepatic ARA content.   The COX-2 enzyme converts 
ARA to eicosanoids with pro-inflammatory properties; therefore, reducing tissue ARA content 
may reduce inflammation.
25
  However, relative gene expression of COX-2 was not significantly 
different among the dietary treatment groups.   
Nf-kB is a major transcription factor of the inflammation pathway. Various studies have 
shown that the omega-3 fatty acid EPA inhibits the phosphorylation of IkBa, preventing its 
degradation and thus, promoting NF-kB inhibition.
26
  Rather than reduced inflammation, in our 
study, histological evaluation showed that rats fed SPI + SB diet also had significantly increased 
portal chronic inflammation compared to other dietary treatment groups.  These results are 
consistent with those by Polavarapu et al
27
 showing male Wistar rats fed fish oil significantly 
increased inflammation compared to feeding corn oil or palm oil.  The authors stated that feeding 
fish oil increased lipid peroxidation which increases susceptibility to oxidative damage and 
worsen liver injury.
27
  The n-3 PUFAs have also been shown to have anti-oxidant effects.  
Supplementation of fish oil in male C57BL/6 mice significantly up-regulated hepatic genetic 
expression levels of Nrf2, a transcription factor in antioxidant response, compared to mice fed 
soybean oil and safflower oil.
28
  In our study Nrf2 expression was not significantly affected by 
dietary intake in the present study. 
 It is well known that females with PKD have a higher risk of developing advanced PLD 
compared to males.  Arnold and Harrison
29
 suggested this could be due a result of hormonal 
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effects created by estrogen.  Soy protein contains phytoestrogens which have weak estrogenic or 
anti-estrogen action.  Therefore, SPI may reduce liver cysts by acting as an anti-estrogen. Rat fed 
SPI as a soybean oil and fish oil blend, but not soybean oil alone showed greater cyst obstruction 
and inflammation.  The results suggested that greater cyst obstruction was due to the fish oil 
inclusion.  This is unexpected since dietary n-3 PUFA consumption has been shown to have anti-
inflammatory properties in the tissue.  However, male Wistar rats (alcohol liver disease) fed fish 
oil experienced significantly increased fatty liver presence, necrosis, and inflammation compared 
to rats fed corn oil and palm oil.
27
  These results suggest that n-PUFA supplementation may 
increase oxidative damage in injured hepatic tissue.   
In the current study there were no histological differences in portal chronic fibrosis 
among the dietary treatment groups.  Although no significant differences were seen in any 
fibrosis gene expression in the current study, n-3 PUFAs have been shown to inhibit mTOR 
expression.
30
  Fibrosis indicates extensive damage.  It is possible that the rats in this study did 
not progress to the phase of liver fibrosis.  Furthermore, there were no differences in liver 
function biomarkers of serum gamma-glutamyl transferase, alanine aminotransferase, albumin, 
or total protein among the dietary treatments  
In conclusion, feeding SPI and/or n-3 PUFAs did not attenuate disease progression or 
severity in female pck rats with PLD. Female pck rats fed SPI + SB diet resulted in higher 
hepatic n-3 PUFA content, but did not decrease inflammation or fibrosis.  Furthermore, feeding 
SPI + SB increased cyst obstruction, portal inflammation, and steatosis suggesting possible 
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Table 1.  Liver histology of female pck rats fed various protein and lipid sources. 
 
Values are the mean ± SEM of n=11-12 rats/group.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy protein isolate; SB, 1:1 
soybean oil:salmon oil blend. 
Measurements Casein + CO Casein + SO SPI + SO SPI + SB P-value 
Cyst effacement 1.82 ± 0.23 2.00 ± 0.19 2.08 ± 0.29 2.46 ± 0.25 0.33 
Cyst obstruction 0.27 ± 0.14 b 0 0.58 ± 0.40 b 1.36 ± 0.49 a 0.03 
Steatosis 1.91 ± 0.32 c 2.46 ± 0.21 b 1.83 ± 0.17 b 3.00 ± 0.23 a 0.003 
Portal chronic inflammation 0.18 ± 0.12 b 0.09 ± 0.09 b 0.50 ± 0.34 b 1.27 ± 0.45 a 0.03 
Portal fibrosis 0 0.36 ± 0.20 0.58 ± 0.29 0.67 ± 0.20 0.27 
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Table 2.  Hepatic tissue fatty acid composition in female pck rats fed various protein and lipid sources. 
Values are the mean ± SEM of n=11-12 rats/group.  Different superscript letters a, b, c within the same rows indicate significant 
differences at P<0.05 by one-way ANOVA followed by Tukey’s test.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy protein 
isolate; SB, 1:1 soybean oil:salmon oil blend; n-6 PUFAs, omega-6 polyunsaturated fatty acids; n-3 PUFAs, omega-3 polyunsaturated 
fatty acids. 
 
Measurements Casein + CO Casein + SO SPI + SO SPI + SB P-value 
Absolute liver weight 9.955 ± 0.20 10.538 ± 0.25 12.606 ± 2.01 13.902 ± 1.60 0.14 
Relative liver weight 36.71 ± 0.73 38.98 ± 0.91 46.66 ± 7.39 49.27 ± 5.24 0.17 
Total Lipid (g lipid/g liver) 0.31 ± 0.03 b 0.29 ± 0.06 b 0.31 ± 0.05 b 0.41 ± 0.03 a <0.05 
n-3 PUFAs
      
Alpha-linolenic acid (18:3) 0.21 ± 0.03 b 1.14 ± 0.13 a 1.25 ± 0.24 a 1.30 ± 0.06 a <0.001 
Eicosapentaenoic acid (20:5) 0.26 ± 0.05 b 0.33 ± 0.03 b 0.44 ± 0.06 b 3.34 ± 0.23 a <0.001 
Docosahexaenoic acid (22:6) 2.18 ± 0.22 c 4.83 ± 0.49 b 4.08 ± 0.85 bc 12.62 ± 0.26 a <0.001 
n-6 PUFAs      
Linoleic acid (18:2) 18.83 ± 1.27 19.67 ± 1.11 21.61 ± 1.38 18.55 ± 0.63 0.28 
Arachadonic acid (20:4) 11.57 ± 1.22 a 10.06 ± 1.20 a 13.34 ± 1.19 a 4.61 ± 1.24 b <0.001 
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Table 3. Liver serum measurements in female pck rats fed various protein and lipid sources. 
 
Values are the mean ± SEM of n=11-12 rats/group.  Different superscript letters a, b, c within the same rows indicate significant 
differences at P<0.05 by one-way ANOVA.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy protein isolate; SB, 1:1 soybean 
oil:salmon oil blend. 
Measurements Casein + CO Casein + SO SPI + SO SPI + SB P-value 
 Gamma-glutamyl transferase 
(U/L)  
3.10 ± 0.84 3.00 ± 0.45 2.50 ± 0.96 4.33 ± 1.02 0.59 
Alanine Aminotransferase 
(U/L) 
91.82 ± 7.30 102.80 ± 14.72 101.55 ± 13.03 89.60 ± 8.81 0.79 
Albumin (g/dL) 3.80 ± 0.15 3.76 ± 0.10 3.56 ± 0.23 3.52 ± 0.16 0.55 
Cholesterol (mg/dL) 144.55 ± 8.74 a 130.40 ± 5.96 b 124.09 ± 6.33 b 77.73 ± 5.80 c <0.001 
Total Protein (g/dL) 6.18 ± 0.35 6.36 ± 0.26 6.52 ± 0.41 6.36 ± 0.33 0.92 
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Table 4. Hepatic relative genetic expression levels of various genes in relation to dietary treatments of pck female rats. 
Values are the mean ± SEM of n=11-12 rats/group.  Different superscript letters a, b, c within the same rows indicate significant 
differences at P<0.05 by one-way ANOVA followed by Tukey’s test.  Abbreviations are CO, corn oil; SO, soybean oil; SPI, soy protein 
isolate; SB, 1:1 soybean oil:salmon oil blend. 
 
Gene Casein + CO Casein + SO SPI + SO SPI + SB P-value 
COX-2 27.87 ± 0.28 28.88 ± 0.70 29.60 ± 0.58 28.07 ± 0.47 0.11 
mTor 30.96 ± 0.26 30.84 ± 0.32 31.54 ± 0.72 31.62 ± 0.65 0.69 
MapK 31.55 ± 0.32 31.74 ± 0.30 31.83 ± 0.16 31.82 ± 0.24 0.24 
PPARγ 25.66 ± 0.74 26.09 ± 0.89 26.09 ± 0.33 26.82 ± 0.19 0.54 
Tgfb1 32.17 ± 0.34 32.31 ± 0.26 32.70 ± 0.16 32.91 ± 0.14 0.12 
Egf 31.22 ± 0.46 31.39 ± 0.34 31.08 ± 0.70 31.19 ± 0.43 0.98 
Sstr3 25.14 ± 0.43 25.10 ± 0.38 25.89 ± 0.51 26.20 ± 0.40 0.24 
Nrf2 36.57 ± 0.32 36.41 ± 0.34 36.38 ± 0.41 36.45 0.30 0.98 
Cftr 31.01 ± 1.49 30.88 ± 0.89 28.76 ± 0.46 30.83 0.28 
At1 35.99 ± 0.33 35.36 ± 0.50 35.39 ± 0.59 35.46 ± 0.19 0.73 
Ikbα 34.75 ± 0.30 35.61 ± 1.01 35.96 ± 0.89 35.52 ± 0.49 0.73 
TNFα 27.89 ± 0.78 29.23 ± 0.61 29.60 ± 0.68 28.76 ± 0.31 0.13 
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6.0 Summary and Conclusion 
    The negative implications and poor prognoses associated with PKD patients, demands the 
need for sound nutrition research that will improve patient quality of life.  Three studies were 
performed in this dissertation to address the role of the bioactive dietary compounds SPI and/or 
n-3 PUFA to attenuation PKD progression, severity, and PKD-related complications using a 
female pck rat model.  The studies concluded: 
 
1. Study 1, female pck rats fed SPI+SO or SPI+SB diet had higher renal DHA tissue 
content than rats fed Casein+SO and Casein + CO, but had no significant effect on 
expression of transcription factors and genes regulating proliferation or inflammation. 
 
2. Study 1, female pck rats fed SPI+SB diet with the highest renal DHA content and 
resulted in significantly higher cyst obstruction and decreased renal function. 
 
3. Study 2, female pck rats fed the SPI+SB diet had significantly higher Ca and P 
retention.  However, bone growth, mineralization, microarchitecture, and strength 
was not significantly enhanced. 
 
4. Study 3, all female pck rats had liver cysts regardless of diet.  Of the dietary 
treatments, rats fed SPI + SB diet had the highest hepatic cyst obstruction, portal 
inflammation, and steatosis. 
 
 
Overall, results from the studies indicated that SPI and/or n-3 PUFA did not delay PKD 
progression, improve bone health or PLD.  Furthermore, the addition of EPA and DHA in the 
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SPI + SB diet led to reduced renal function, and liver steatosis and inflammation.  It is possible 
that in injured renal and hepatic tissue, n-3 fatty acid supplementation may increase oxidation 
and overall PKD severity as shown in the study by Polavarapu et al 1998.   
In the absence of large human clinical trials that include dietary intervention for PKD, 
recommendations for PKD patients must rely on evidence from animal studies.  Most dietary 
studies have used the Han:SPRD-cy rat, a non-orthologous genetic model of ADPKD.  Also, the 
majority of the animal studies have focused on males, despite the existence of gender differences 
in PKD progression and nutrient metabolism.  Therefore, the novel information regarding the 
effects and potential role of dietary components on molecular mechanisms obtained from studies 
in this thesis using the pck rat models of PKD can benefit human PKD patients by providing a 
better understanding of pathways to target in order to inhibit cyst pathogenesis that will allow 
clinicians to better treat PKD patients. 
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7.0  Future Studies 
 Due to the novelty of this research, it is not surprising that the results raises many new 
questions.  One potential area that could be further investigated is dietary lipid and protein 
dosages.  Although, lipid and protein doses in the present studies were consistent with past 
studies, it is may not be physiologically relevant to humans.   For example, most animal studies 
have use 7% to 20% (wt) diet of pure oil, which is unlikely to occur in the human diet.  
Furthermore, in renal failure, patients are often advised to reduce protein intake to minimize 
nitrogenous load on the renal system.  A future study could determine multiple lipid and protein 
doses in PKD models to determine optimal doses for beneficial results.  Another potential study 
would be performing RNA-seq on the renal and hepatic tissues which will allow global 
assessment of which genes and pathways were up-regulated or down-regulated due to dietary 
components.  Since the full pathophysiology of PKD is unknown, this would provide vital 
information for understanding PKD and potential role of diet in the treatment of this genetic 
disease.  However, rat tissues from the current study may not provide the best representation of 
up/down-regulated pathways.  It may be beneficial to conduct RNA-seq on rat tissues at various 
points during a new feeding study.  Also, to determine if diet truly is beneficial, it would helpful 
to examine a feeding study comparing both healthy (control) and diseased (experimental) 
animals.  Due to the extensive damage associated with PKD and its related complications, it is 
quite possible that diet therapy alone may not reverse the disease process.  Therefore, it may be 
beneficial to examine the effects of diet in addition to a pharmalogical agent to maximize 
beneficial results.  Lastly, although most dietary treatments are successful when administered at 
weaning, it may be beneficial to conduct a study examining dietary treatment in utero since PKD 
manifests early, particularly ADPKD which has infantile onset.  It also may be beneficial to 
examine the role of diet directly after birth, to maximize results.  
